[S02DA03, antipyrine, The risk or severity of renal failure can be increased when Antipyrine is combined with Tacrolimus.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Tacrolimus.]
[J01GA01, streptomycin, Tacrolimus may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, Tacrolimus may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).]
[L01AD04, streptozocin, Tacrolimus may increase the immunosuppressive activities of Streptozocin.]
[L04AA27, fingolimod, Tacrolimus may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tacrolimus.]
[A02BX02, sucralfate, Tacrolimus may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Tacrolimus may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Tacrolimus.]
[J01EC01, sulfamethoxazole, The serum concentration of Tacrolimus can be increased when it is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Tacrolimus can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Tacrolimus.]
[M01AB02, sulindac, The risk or severity of renal failure can be increased when Sulindac is combined with Tacrolimus.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Tacrolimus.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Tacrolimus.]
[M01AX04, apazone, The risk or severity of renal failure can be increased when Azapropazone is combined with Tacrolimus.]
[L01BB02, mercaptopurine, Tacrolimus may increase the immunosuppressive activities of Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Tacrolimus.]
[L02BA01, tamoxifen, The serum concentration of Tacrolimus can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Tacrolimus may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The serum concentration of Tacrolimus can be increased when it is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Tacrolimus.]
[G03BA03, testosterone, The metabolism of Tacrolimus can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Tetrabenazine.]
[S03AA02, tetracycline, The serum concentration of Tacrolimus can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Tacrolimus.]
[N04BC07, apomorphine, The metabolism of Tacrolimus can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, Tacrolimus may increase the immunosuppressive activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Tacrolimus.]
[P02CA02, thiabendazole, Tacrolimus may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, Tacrolimus may increase the immunosuppressive activities of Eribulin.]
[R06AD03, thiethylperazine, Tacrolimus may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, Tacrolimus may increase the immunosuppressive activities of Thiotepa.]
[L01BB03, thioguanine, Tacrolimus may increase the immunosuppressive activities of Tioguanine.]
[N05CA19, thiopental, The serum concentration of Tacrolimus can be increased when it is combined with Thiopental.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Thiothixene.]
[G04BE06, moxisylyte, Tacrolimus may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Tacrolimus may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Tacrolimus.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Tacrolimus.]
[P01AB02, tinidazole, Tacrolimus may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Tacrolimus may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Tacrolimus.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus.]
[M02AA21, tolmetin, The risk or severity of renal failure can be increased when Tolmetin is combined with Tacrolimus.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Tacrolimus.]
[N06AF04, tranylcypromine, The serum concentration of Tacrolimus can be increased when it is combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Tacrolimus.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tacrolimus.]
[L01XF01, tretinoin, Tacrolimus may increase the immunosuppressive activities of Tretinoin.]
[S01BA05, triamcinolone, Tacrolimus may increase the immunosuppressive activities of Triamcinolone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.]
[N05CD05, triazolam, The metabolism of Tacrolimus can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Tacrolimus.]
[A16AX12, trientine, Tacrolimus may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Tacrolimus may increase the immunosuppressive activities of Trifluridine.]
[S01BA09, clobetasone, Tacrolimus may increase the immunosuppressive activities of Clobetasone.]
[S01BA10, alclometasone, Tacrolimus may increase the immunosuppressive activities of Alclometasone.]
[D07AC02, fluclorolone, Tacrolimus may increase the immunosuppressive activities of Fluclorolone.]
[R03BA07, mometasone, Tacrolimus may increase the immunosuppressive activities of Mometasone.]
[A03AA05, trimebutine, Trimebutine may increase the immunosuppressive activities of Tacrolimus.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the immunosuppressive activities of Tacrolimus.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Tacrolimus.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Tacrolimus.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Tacrolimus.]
[J01FA08, troleandomycin, The serum concentration of Tacrolimus can be increased when it is combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Tacrolimus.]
[L04AA26, belimumab, Tacrolimus may increase the immunosuppressive activities of Belimumab.]
[L01FX04, ipilimumab, Tacrolimus may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Tacrolimus.]
[R02AA14, oxyquinoline, Tacrolimus may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Tacrolimus can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Tacrolimus can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Tacrolimus can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Tacrolimus can be increased when it is combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Tacrolimus.]
[S01AA28, vancomycin, Tacrolimus may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, Tacrolimus may increase the immunosuppressive activities of Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ezogabine.]
[B01AF01, rivaroxaban, The metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Tacrolimus.]
[B01AC24, ticagrelor, The serum concentration of Tacrolimus can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Tacrolimus can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The serum concentration of Tacrolimus can be increased when it is combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Tacrolimus can be increased when it is combined with Vinblastine.]
[L01CA02, vincristine, Tacrolimus may increase the immunosuppressive activities of Vincristine.]
[L01CA03, vindesine, Tacrolimus may increase the immunosuppressive activities of Vindesine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tacrolimus.]
[A11HA03, vitamin E, The metabolism of Tacrolimus can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Tacrolimus.]
[J05AF01, zidovudine, Tacrolimus may increase the immunosuppressive activities of Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Tacrolimus can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Tacrolimus can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tacrolimus.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Tacrolimus.]
[L01FX05, brentuximab vedotin, The serum concentration of Tacrolimus can be increased when it is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Tiludronic acid.]
[B06AC02, icatibant, Tacrolimus may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Tacrolimus can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.]
[R03DC01, zafirlukast, The serum concentration of Tacrolimus can be increased when it is combined with Zafirlukast.]
[A02BC04, rabeprazole, The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Tacrolimus can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Tacrolimus may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.]
[N02BA01, aspirin, The risk or severity of renal failure can be increased when Acetylsalicylic acid is combined with Tacrolimus.]
[L01EJ01, ruxolitinib, Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Tolterodine.]
[J01DH04, doripenem, Tacrolimus may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Atenolol is combined with Tacrolimus.]
[L03AB11, peginterferon alfa-2a, Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2a.]
[L01FA01, rituximab, Tacrolimus may increase the immunosuppressive activities of Rituximab.]
[J02AC03, voriconazole, The serum concentration of Tacrolimus can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Atropine.]
[M01CB03, auranofin, Tacrolimus may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.]
[R07AX02, ivacaftor, The serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, Tacrolimus may increase the immunosuppressive activities of Prednylidene.]
[B03XA04, peginesatide, Tacrolimus may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Tacrolimus may increase the immunosuppressive activities of Azacitidine.]
[L04AX01, azathioprine, Tacrolimus may increase the immunosuppressive activities of Azathioprine.]
[L01BC05, gemcitabine, Tacrolimus may increase the immunosuppressive activities of Gemcitabine.]
[J01DF01, aztreonam, Tacrolimus may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Tacrolimus.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tacrolimus.]
[M03BX01, baclofen, Tacrolimus may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Tacrolimus.]
[L01FX02, gemtuzumab ozogamicin, Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Tacrolimus may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Tacrolimus.]
[L01XG02, carfilzomib, Tacrolimus may increase the immunosuppressive activities of Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Tacrolimus can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Tacrolimus can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus.]
[L04AA31, teriflunomide, Tacrolimus may increase the immunosuppressive activities of Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Tacrolimus.]
[L04AA22, abetimus, Tacrolimus may increase the immunosuppressive activities of Abetimus.]
[H02AA01, aldosterone, Tacrolimus may increase the immunosuppressive activities of Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Tacrolimus can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Tacrolimus can be increased when combined with Barbital.]
[D02BA02, octinoxate, Tacrolimus may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The serum concentration of Tacrolimus can be increased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, Tacrolimus may increase the immunosuppressive activities of Bendamustine.]
[N04BD02, rasagiline, Tacrolimus may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, Lercanidipine may increase the immunosuppressive activities of Tacrolimus.]
[N03AX22, perampanel, The metabolism of Tacrolimus can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Tacrolimus.]
[V09IX04, fluorodeoxyglucose F18, Tacrolimus may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The serum concentration of Tacrolimus can be increased when it is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Tacrolimus can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Tacrolimus may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, Tacrolimus may increase the immunosuppressive activities of Ponatinib.]
[B01AF02, apixaban, The metabolism of Tacrolimus can be decreased when combined with Apixaban.]
[A16AX08, teduglutide, Tacrolimus may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Tacrolimus.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Bedaquiline.]
[C04AX11, bencyclane, Bencyclane may increase the immunosuppressive activities of Tacrolimus.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Tacrolimus can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Tacrolimus.]
[L04AX06, pomalidomide, Tacrolimus may increase the immunosuppressive activities of Pomalidomide.]
[N02BA10, benorilate, The risk or severity of renal failure can be increased when Benorilate is combined with Tacrolimus.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.]
[L04AX07, dimethyl fumarate, Tacrolimus may increase the immunosuppressive activities of Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Tacrolimus.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Tacrolimus.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Tacrolimus.]
[J02AX04, caspofungin, The serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin.]
[L03AA12, ancestim, Tacrolimus may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of renal failure can be increased when Celecoxib is combined with Tacrolimus.]
[L04AA18, everolimus, The serum concentration of Tacrolimus can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Tacrolimus.]
[L01EC02, dabrafenib, The serum concentration of Tacrolimus can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of renal failure can be increased when Benzydamine is combined with Tacrolimus.]
[L01EE01, trametinib, Tacrolimus may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Tacrolimus may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Tacrolimus.]
[N06AX28, levomilnacipran, Tacrolimus may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Tacrolimus.]
[C08EA02, bepridil, Bepridil may increase the immunosuppressive activities of Tacrolimus.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Tacrolimus.]
[L03AA14, lipegfilgrastim, Tacrolimus may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Tacrolimus.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Tacrolimus.]
[C02KX04, macitentan, Tacrolimus may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Tacrolimus.]
[N06AX26, vortioxetine, The metabolism of Tacrolimus can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, Tacrolimus may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Tacrolimus can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Tacrolimus can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Tacrolimus.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tacrolimus.]
[C01CA27, droxidopa, Tacrolimus may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tacrolimus can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Tacrolimus can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Tacrolimus may increase the immunosuppressive activities of Apremilast.]
[L02BG02, formestane, The metabolism of Tacrolimus can be increased when combined with Formestane.]
[S03BA03, betamethasone, Tacrolimus may increase the immunosuppressive activities of Betamethasone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tacrolimus.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Tacrolimus.]
[V03AB34, fomepizole, Tacrolimus may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, Tacrolimus may increase the nephrotoxic activities of Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Tacrolimus.]
[L04AC11, siltuximab, The serum concentration of Tacrolimus can be increased when it is combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Tacrolimus can be increased when it is combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Tacrolimus can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, Tacrolimus may increase the immunosuppressive activities of Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tacrolimus.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Tacrolimus.]
[L01XH04, belinostat, Tacrolimus may increase the immunosuppressive activities of Belinostat.]
[L01EM01, idelalisib, The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, Tacrolimus may increase the immunosuppressive activities of Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Tacrolimus may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Tacrolimus may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Tacrolimus can be decreased when combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Tacrolimus.]
[J01XA05, oritavancin, The metabolism of Tacrolimus can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Dihydrostreptomycin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tacrolimus.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Tacrolimus.]
[L01BC08, decitabine, Tacrolimus may increase the immunosuppressive activities of Decitabine.]
[L04AX05, pirfenidone, Tacrolimus may increase the immunosuppressive activities of Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Tacrolimus can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Tacrolimus may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, Tacrolimus may increase the immunosuppressive activities of Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Tacrolimus.]
[L01XK01, olaparib, The serum concentration of Tacrolimus can be increased when it is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Tacrolimus.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Tacrolimus.]
[N06AX11, mirtazapine, The serum concentration of Tacrolimus can be increased when it is combined with Mirtazapine.]
[L04AC10, secukinumab, Tacrolimus may increase the immunosuppressive activities of Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Tacrolimus.]
[L01XH03, panobinostat, Tacrolimus may increase the immunosuppressive activities of Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Tacrolimus can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The serum concentration of Tacrolimus can be increased when it is combined with Acetaminophen.]
[L01DC01, bleomycin, Tacrolimus may increase the immunosuppressive activities of Bleomycin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Tacrolimus.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Tacrolimus.]
[J05AP06, asunaprevir, The metabolism of Tacrolimus can be increased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Tacrolimus.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Tacrolimus.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Tacrolimus.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Tacrolimus.]
[M02AA25, aceclofenac, The risk or severity of renal failure can be increased when Aceclofenac is combined with Tacrolimus.]
[M01AB11, acemetacin, The risk or severity of renal failure can be increased when Acemetacin is combined with Tacrolimus.]
[S01EC01, acetazolamide, The serum concentration of Tacrolimus can be increased when it is combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Tacrolimus.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Acipimox.]
[A02BC03, lansoprazole, The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.]
[V03AB37, idarucizumab, Tacrolimus may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, Tacrolimus may increase the immunosuppressive activities of Trabectedin.]
[R03DX09, mepolizumab, Tacrolimus may increase the immunosuppressive activities of Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Tacrolimus can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Tacrolimus.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tacrolimus.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Tacrolimus.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Tacrolimus.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Tacrolimus.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Tacrolimus.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Tacrolimus.]
[M04AB05, lesinurad, The metabolism of Tacrolimus can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Tacrolimus can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Tacrolimus.]
[N05CA05, aprobarbital, The metabolism of Tacrolimus can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of renal failure can be increased when Alminoprofen is combined with Tacrolimus.]
[N03AX23, brivaracetam, Tacrolimus may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L04AC13, ixekizumab, Tacrolimus may increase the immunosuppressive activities of Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Tacrolimus can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Tacrolimus may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The serum concentration of Tacrolimus can be increased when it is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Tacrolimus may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[D07AC11, amcinonide, Tacrolimus may increase the immunosuppressive activities of Amcinonide.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tacrolimus.]
[C08CA01, amlodipine, Amlodipine may increase the immunosuppressive activities of Tacrolimus.]
[N05AX17, pimavanserin, The metabolism of Tacrolimus can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Bumetanide.]
[N01BB01, bupivacaine, Tacrolimus may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Bupranolol.]
[N07BC01, buprenorphine, The serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Tacrolimus can be decreased when combined with Buspirone.]
[L01AB01, busulfan, Tacrolimus may increase the immunosuppressive activities of Busulfan.]
[L01XX27, arsenic trioxide, Tacrolimus may increase the immunosuppressive activities of Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Tacrolimus can be decreased when combined with Artemether.]
[M02AA03, clofezone, The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Tacrolimus.]
[S01GX07, azelastine, The serum concentration of Tacrolimus can be increased when it is combined with Azelastine.]
[L01XK03, rucaparib, The serum concentration of Tacrolimus can be increased when it is combined with Rucaparib.]
[S01AA26, azithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin.]
[L04AC12, brodalumab, Tacrolimus may increase the immunosuppressive activities of Brodalumab.]
[L01EF02, ribociclib, The serum concentration of Tacrolimus can be increased when it is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of renal failure can be increased when Balsalazide is combined with Tacrolimus.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Tacrolimus.]
[A06AH05, naldemedine, Tacrolimus may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Tacrolimus can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Tacrolimus.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Tacrolimus.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Tacrolimus.]
[D05AX03, calcitriol, The metabolism of Tacrolimus can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Tacrolimus may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, Tacrolimus may increase the immunosuppressive activities of Daclizumab.]
[J01XX08, linezolid, Tacrolimus may increase the immunosuppressive activities of Linezolid.]
[J05AF06, abacavir, Tacrolimus may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Tacrolimus can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Tacrolimus can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, Tacrolimus may increase the immunosuppressive activities of Infliximab.]
[L01EX10, midostaurin, The serum concentration of Tacrolimus can be increased when it is combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Tacrolimus.]
[L04AC14, sarilumab, The serum concentration of Tacrolimus can be increased when it is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Tacrolimus.]
[L04AC16, guselkumab, Tacrolimus may increase the immunosuppressive activities of Guselkumab.]
[D01AC10, bifonazole, The serum concentration of Tacrolimus can be increased when it is combined with Bifonazole.]
[P03AC02, bioallethrin, Bioallethrin may increase the immunosuppressive activities of Tacrolimus.]
[L01BC06, capecitabine, Tacrolimus may increase the immunosuppressive activities of Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Tacrolimus can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Tacrolimus.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tacrolimus.]
[L01XH01, vorinostat, Tacrolimus may increase the immunosuppressive activities of Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Tacrolimus.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Tacrolimus.]
[J05AG03, efavirenz, The serum concentration of Tacrolimus can be increased when it is combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefprozil.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Bopindolol.]
[L04AC02, basiliximab, Tacrolimus may increase the immunosuppressive activities of Basiliximab.]
[L01BA03, raltitrexed, Tacrolimus may increase the immunosuppressive activities of Raltitrexed.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Tacrolimus.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Canrenone is combined with Tacrolimus.]
[R03BA02, budesonide, Tacrolimus may increase the immunosuppressive activities of Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Tacrolimus.]
[M01AB07, bumadizone, The risk or severity of renal failure can be increased when Bumadizone is combined with Tacrolimus.]
[L01EL02, acalabrutinib, The serum concentration of Tacrolimus can be increased when it is combined with Acalabrutinib.]
[J05AX18, letermovir, The serum concentration of Tacrolimus can be increased when it is combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Tacrolimus may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Tacrolimus.]
[N01BX04, capsaicin, The serum concentration of Tacrolimus can be increased when it is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Tacrolimus.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Tacrolimus can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Tacrolimus may increase the immunosuppressive activities of Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Tacrolimus.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-n1.]
[C07AG02, carvedilol, Carvedilol may increase the immunosuppressive activities of Tacrolimus.]
[B02BX09, fostamatinib, The serum concentration of Tacrolimus can be increased when it is combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Tacrolimus can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Tacrolimus.]
[L04AA37, baricitinib, Tacrolimus may increase the immunosuppressive activities of Baricitinib.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefpodoxime.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Tacrolimus.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftibuten.]
[J01GB14, plazomicin, Tacrolimus may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Tacrolimus.]
[L01XX62, ivosidenib, The metabolism of Tacrolimus can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Tacrolimus may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Tacrolimus can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Tacrolimus.]
[J05AX24, tecovirimat, The metabolism of Tacrolimus can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Tacrolimus can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Tacrolimus can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Tacrolimus.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Tacrolimus.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Tacrolimus.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Tacrolimus.]
[D08AE05, chloroxylenol, Tacrolimus may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of renal failure can be increased when Lornoxicam is combined with Tacrolimus.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Tacrolimus.]
[R03BB08, revefenacin, Tacrolimus may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Tacrolimus can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, Tacrolimus may increase the immunosuppressive activities of Emapalumab.]
[L01AD01, carmustine, Tacrolimus may increase the immunosuppressive activities of Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Tacrolimus.]
[L01EX13, gilteritinib, The metabolism of Tacrolimus can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amifampridine.]
[L04AA43, ravulizumab, Tacrolimus may increase the immunosuppressive activities of Ravulizumab.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Tacrolimus.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Tacrolimus.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Tacrolimus.]
[C10AB08, ciprofibrate, Tacrolimus may increase the nephrotoxic activities of Ciprofibrate.]
[P02BX04, triclabendazole, The serum concentration of Tacrolimus can be increased when it is combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Tacrolimus can be increased when combined with Esketamine.]
[L04AA42, siponimod, Tacrolimus may increase the immunosuppressive activities of Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, Tacrolimus may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Tacrolimus.]
[N05BA09, clobazam, The metabolism of Tacrolimus can be increased when combined with Clobazam.]
[D07AB21, clocortolone, Tacrolimus may increase the immunosuppressive activities of Clocortolone.]
[H02AB14, cloprednol, Tacrolimus may increase the immunosuppressive activities of Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ubidecarenone.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Candesartan.]
[L04AB01, etanercept, Tacrolimus may increase the immunosuppressive activities of Etanercept.]
[V03AE02, sevelamer, The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer.]
[H02AB17, cortivazol, Tacrolimus may increase the immunosuppressive activities of Cortivazol.]
[L04AC18, risankizumab, Tacrolimus may increase the immunosuppressive activities of Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Tacrolimus can be increased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Tacrolimus.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefazolin.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Tacrolimus.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Tacrolimus.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefonicid.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Tacrolimus.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tacrolimus.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Tacrolimus.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tacrolimus.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefuroxime.]
[L04AA44, upadacitinib, Tacrolimus may increase the immunosuppressive activities of Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Tacrolimus.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Tacrolimus can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Tacrolimus can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Tacrolimus.]
[N04CX01, istradefylline, The metabolism of Tacrolimus can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Tacrolimus.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Tacrolimus.]
[J01DB01, cephalexin, The metabolism of Tacrolimus can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Tacrolimus.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefapirin.]
[J01DB09, cephradine, The metabolism of Tacrolimus can be increased when combined with Cefradine.]
[H02AB13, deflazacort, Tacrolimus may increase the immunosuppressive activities of Deflazacort.]
[L01FD01, trastuzumab, Tacrolimus may increase the immunosuppressive activities of Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, Tacrolimus may increase the immunosuppressive activities of Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Tacrolimus.]
[L04AX09, diroximel fumarate, Tacrolimus may increase the immunosuppressive activities of Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Tacrolimus.]
[B06AX03, voxelotor, The serum concentration of Tacrolimus can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Tacrolimus can be increased when it is combined with Cenobamate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Givosiran.]
[M09AX08, golodirsen, Tacrolimus may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Tacrolimus.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tacrolimus.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tacrolimus.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Tacrolimus may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N05CM21, lemborexant, The metabolism of Tacrolimus can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tacrolimus can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, Tacrolimus may increase the immunosuppressive activities of Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Tacrolimus.]
[J05AB16, remdesivir, The serum concentration of Tacrolimus can be increased when it is combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Tacrolimus can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Tacrolimus can be increased when it is combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Tacrolimus can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Tacrolimus may increase the immunosuppressive activities of Ozanimod.]
[L01EE04, selumetinib, The metabolism of Tacrolimus can be decreased when combined with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Tacrolimus may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Tacrolimus may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[D07AC19, difluprednate, Tacrolimus may increase the immunosuppressive activities of Difluprednate.]
[M01AH02, rofecoxib, The risk or severity of renal failure can be increased when Rofecoxib is combined with Tacrolimus.]
[L01XF03, bexarotene, Tacrolimus may increase the immunosuppressive activities of Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Tacrolimus can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Dirithromycin.]
[L01AA02, chlorambucil, Tacrolimus may increase the immunosuppressive activities of Chlorambucil.]
[S03AA08, chloramphenicol, The serum concentration of Tacrolimus can be increased when it is combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Chlorcyclizine.]
[N02BA03, choline salicylate, Tacrolimus may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Tacrolimus may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Tacrolimus.]
[V09AA01, technetium Tc 99m exametazime, Tacrolimus may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Tacrolimus may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[V04CH02, indigo carmine, Tacrolimus may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, Tacrolimus may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The serum concentration of Tacrolimus can be increased when it is combined with Valproic acid.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, Tacrolimus may increase the immunosuppressive activities of Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The serum concentration of Tacrolimus can be increased when it is combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Pipemidic acid.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Tacrolimus.]
[D07XB03, fluprednidene, Tacrolimus may increase the immunosuppressive activities of Fluprednidene.]
[M01AC04, droxicam, The risk or severity of renal failure can be increased when Droxicam is combined with Tacrolimus.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Tacrolimus.]
[V08CA05, mangafodipir, Tacrolimus may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.]
[M02AA27, dexketoprofen, The risk or severity of renal failure can be increased when Dexketoprofen is combined with Tacrolimus.]
[L04AA47, inebilizumab, Tacrolimus may increase the immunosuppressive activities of Inebilizumab.]
[R05CB11, stepronin, Tacrolimus may increase the immunosuppressive activities of Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Tacrolimus can be increased when it is combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Tacrolimus can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Tacrolimus.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus.]
[L04AC19, satralizumab, The serum concentration of Tacrolimus can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Tacrolimus can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Tacrolimus can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Tacrolimus.]
[R06AB04, chlorpheniramine, The metabolism of Tacrolimus can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Tacrolimus can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, Tacrolimus may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Tacrolimus.]
[N02BA07, ethenzamide, The risk or severity of renal failure can be increased when Ethenzamide is combined with Tacrolimus.]
[N06BX18, vinpocetine, Vinpocetine may increase the immunosuppressive activities of Tacrolimus.]
[M01AB08, etodolac, The risk or severity of renal failure can be increased when Etodolac is combined with Tacrolimus.]
[M02AA06, etofenamate, The risk or severity of renal failure can be increased when Etofenamate is combined with Tacrolimus.]
[C10AB09, etofibrate, Tacrolimus may increase the nephrotoxic activities of Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Tacrolimus.]
[A16AX20, lonafarnib, The serum concentration of Tacrolimus can be increased when it is combined with Lonafarnib.]
[L01BB05, fludarabine, Tacrolimus may increase the immunosuppressive activities of Fludarabine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Tacrolimus.]
[M01AX25, chondroitin sulfates, Tacrolimus may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, Tacrolimus may increase the immunosuppressive activities of Voclosporin.]
[P03AX07, abametapir, The serum concentration of Tacrolimus can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Tacrolimus.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Tacrolimus.]
[N03AX10, felbamate, The metabolism of Tacrolimus can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of renal failure can be increased when Fenbufen is combined with Tacrolimus.]
[C01CA19, fenoldopam, Tacrolimus may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Tacrolimus can be decreased when combined with Finasteride.]
[J01DD15, cefdinir, Tacrolimus may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Flumequine.]
[R03BA03, flunisolide, Tacrolimus may increase the immunosuppressive activities of Flunisolide.]
[S02BA08, fluocinolone acetonide, Tacrolimus may increase the immunosuppressive activities of Fluocinolone acetonide.]
[N02BG07, flupirtine, Tacrolimus may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Tacrolimus.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Tacrolimus.]
[L03AB10, peginterferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tacrolimus.]
[A02BA01, cimetidine, The serum concentration of Tacrolimus can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Tacrolimus may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the immunosuppressive activities of Tacrolimus.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Tacrolimus can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Tacrolimus can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The serum concentration of Tacrolimus can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Tacrolimus may increase the immunosuppressive activities of Cisplatin.]
[N06AB04, citalopram, The serum concentration of Tacrolimus can be increased when it is combined with Citalopram.]
[L04AA54, pegcetacoplan, Tacrolimus may increase the immunosuppressive activities of Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Tacrolimus.]
[L04AA48, belumosudil, Tacrolimus may increase the immunosuppressive activities of Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Tacrolimus can be increased when it is combined with Fexinidazole.]
[L04AA51, anifrolumab, Tacrolimus may increase the immunosuppressive activities of Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Tacrolimus can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Tacrolimus.]
[L04AA59, avacopan, The metabolism of Tacrolimus can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of renal failure can be increased when Mefenamic acid is combined with Tacrolimus.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus.]
[J01FF01, clindamycin, The serum concentration of Tacrolimus can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Tacrolimus can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Tacrolimus can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Tacrolimus can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, Tacrolimus may increase the immunosuppressive activities of Clobetasol.]
[J04BA01, clofazimine, The serum concentration of Tacrolimus can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Tacrolimus.]
[C10AB01, clofibrate, Tacrolimus may increase the nephrotoxic activities of Clofibrate.]
[B06AX04, mitapivat, The metabolism of Tacrolimus can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Tacrolimus may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Tacrolimus can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Tacrolimus.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Tacrolimus.]
[N03AE01, clonazepam, Tacrolimus may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Tacrolimus.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Tacrolimus.]
[C01EB24, mavacamten, The serum concentration of Tacrolimus can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Tacrolimus may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Tacrolimus.]
[A02BC08, vonoprazan, The metabolism of Tacrolimus can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, Tacrolimus may increase the immunosuppressive activities of Spesolimab.]
[L04AA56, deucravacitinib, Tacrolimus may increase the immunosuppressive activities of Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Tacrolimus can be decreased when combined with Ondansetron.]
[G01AF02, clotrimazole, The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Tacrolimus can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The serum concentration of Tacrolimus can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The serum concentration of Tacrolimus can be increased when it is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Tacrolimus.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Tacrolimus.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Tacrolimus.]
[J01GB12, arbekacin, Tacrolimus may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, Tacrolimus may increase the immunosuppressive activities of Halometasone.]
[H01AC08, somatrogon, The metabolism of Tacrolimus can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cocaine.]
[L04AC21, bimekizumab, Tacrolimus may increase the immunosuppressive activities of Bimekizumab.]
[M01AX13, proquazone, The risk or severity of renal failure can be increased when Proquazone is combined with Tacrolimus.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Tacrolimus.]
[J01XB01, colistin, Tacrolimus may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefpirome.]
[L04AA13, leflunomide, Tacrolimus may increase the immunosuppressive activities of Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Desflurane.]
[A04AA03, tropisetron, Tacrolimus may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The metabolism of Tacrolimus can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure can be increased when Imidazole salicylate is combined with Tacrolimus.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Tacrolimus.]
[L01BB07, nelarabine, Tacrolimus may increase the immunosuppressive activities of Nelarabine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Tacrolimus.]
[J01FA15, telithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, Tacrolimus may increase the immunosuppressive activities of Ciclesonide.]
[B01AC10, indobufen, The risk or severity of renal failure can be increased when Indobufen is combined with Tacrolimus.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Desloratadine.]
[J05AB14, valganciclovir, Tacrolimus may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Tacrolimus may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Tacrolimus may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Tacrolimus may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Tacrolimus may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Tacrolimus may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of renal failure can be increased when Valdecoxib is combined with Tacrolimus.]
[N02CC05, almotriptan, Tacrolimus may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of renal failure can be increased when Parecoxib is combined with Tacrolimus.]
[J02AC02, itraconazole, The serum concentration of Tacrolimus can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Tacrolimus.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Emedastine.]
[N05BA10, ketazolam, The serum concentration of Tacrolimus can be increased when it is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of renal failure can be increased when Kebuzone is combined with Tacrolimus.]
[L01EA01, imatinib, The serum concentration of Tacrolimus can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Tacrolimus can be increased when it is combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Tacrolimus can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, Lacidipine may increase the immunosuppressive activities of Tacrolimus.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Tacrolimus.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Tacrolimus.]
[S01BA03, cortisone, The metabolism of Tacrolimus can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of renal failure can be increased when Lonazolac is combined with Tacrolimus.]
[M02AA31, loxoprofen, The risk or severity of renal failure can be increased when Loxoprofen is combined with Tacrolimus.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tacrolimus.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Tacrolimus.]
[A06AD01, magnesium carbonate, Tacrolimus may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The serum concentration of Tacrolimus can be increased when it is combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Mebeverine.]
[S01BA08, medrysone, Tacrolimus may increase the immunosuppressive activities of Medrysone.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Mepindolol.]
[H02AB15, meprednisone, Tacrolimus may increase the immunosuppressive activities of Meprednisone.]
[R06AD07, mequitazine, The serum concentration of Tacrolimus can be increased when it is combined with Mequitazine.]
[J01DH02, meropenem, Tacrolimus may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Adenosine.]
[C04AX01, cyclandelate, Cyclandelate may increase the immunosuppressive activities of Tacrolimus.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cyclizine.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tacrolimus.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Melperone.]
[L04AA15, alefacept, Tacrolimus may increase the immunosuppressive activities of Alefacept.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Tacrolimus.]
[J01FA03, midecamycin, The serum concentration of Tacrolimus can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Tacrolimus.]
[J05AF07, tenofovir disoproxil, Tacrolimus may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, Tacrolimus may increase the immunosuppressive activities of Cyclophosphamide.]
[S01XA18, cyclosporine, Tacrolimus may increase the nephrotoxic activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Tacrolimus can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Tacrolimus.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Tacrolimus.]
[C10AA07, rosuvastatin, The metabolism of Tacrolimus can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of renal failure can be increased when Mofebutazone is combined with Tacrolimus.]
[M01AX22, morniflumate, The risk or severity of renal failure can be increased when Morniflumate is combined with Tacrolimus.]
[C03XA02, conivaptan, The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan.]
[L01BC01, cytarabine, Tacrolimus may increase the immunosuppressive activities of Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Tacrolimus.]
[M01AH05, etoricoxib, The serum concentration of Tacrolimus can be increased when it is combined with Etoricoxib.]
[L01AX04, dacarbazine, Tacrolimus may increase the immunosuppressive activities of Dacarbazine.]
[L01DA01, dactinomycin, Tacrolimus may increase the immunosuppressive activities of Dactinomycin.]
[G03XA01, danazol, The serum concentration of Tacrolimus can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Tacrolimus can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of renal failure can be increased when Nabumetone is combined with Tacrolimus.]
[N07BB05, nalmefene, Tacrolimus may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Tacrolimus.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nebivolol.]
[S01GX04, nedocromil, Tacrolimus may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The serum concentration of Tacrolimus can be increased when it is combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nicorandil.]
[L02BB02, nilutamide, Tacrolimus may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Tacrolimus may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, Tacrolimus may increase the immunosuppressive activities of Pimecrolimus.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of renal failure can be increased when Olsalazine is combined with Tacrolimus.]
[N06AA01, desipramine, The serum concentration of Tacrolimus can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, Tacrolimus may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[S01BA11, desonide, Tacrolimus may increase the immunosuppressive activities of Desonide.]
[D07XC02, desoximetasone, Tacrolimus may increase the immunosuppressive activities of Desoximetasone.]
[J01DH03, ertapenem, The serum concentration of Tacrolimus can be increased when it is combined with Ertapenem.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Aliskiren.]
[L01XA03, oxaliplatin, Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of renal failure can be increased when Oxaprozin is combined with Tacrolimus.]
[N03AF02, oxcarbazepine, The serum concentration of Tacrolimus can be increased when it is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Tacrolimus can be increased when it is combined with Dexamethasone.]
[G04BD04, oxybutynin, The serum concentration of Tacrolimus can be increased when it is combined with Oxybutynin.]
[L04AB04, adalimumab, Tacrolimus may increase the immunosuppressive activities of Adalimumab.]
[L01EB01, gefitinib, The metabolism of Tacrolimus can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Tacrolimus may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Tacrolimus can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The serum concentration of Tacrolimus can be increased when it is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Tacrolimus can be decreased when combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Tacrolimus may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[A03AX15, peppermint oil, The serum concentration of Tacrolimus can be increased when it is combined with Peppermint oil.]
[P03AC04, permethrin, Tacrolimus may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The serum concentration of Tacrolimus can be increased when it is combined with Diazepam.]
[R05DA08, pholcodine, Tacrolimus may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of renal failure can be increased when Diclofenac is combined with Tacrolimus.]
[J01CF01, dicloxacillin, The metabolism of Tacrolimus can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Foscarnet.]
[A03AA07, dicyclomine, Tacrolimus may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Tacrolimus may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, Pinaverium may increase the immunosuppressive activities of Tacrolimus.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus.]
[L01DC04, ixabepilone, Tacrolimus may increase the immunosuppressive activities of Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Tacrolimus can be increased when it is combined with Erlotinib.]
[L01DB08, pirarubicin, Tacrolimus may increase the immunosuppressive activities of Pirarubicin.]
[L02AA01, diethylstilbestrol, The serum concentration of Tacrolimus can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The serum concentration of Tacrolimus can be increased when it is combined with Isradipine.]
[D07XC04, diflucortolone, Tacrolimus may increase the immunosuppressive activities of Difluocortolone.]
[N02BA11, diflunisal, The risk or severity of renal failure can be increased when Diflunisal is combined with Tacrolimus.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Tacrolimus.]
[C01AA05, digoxin, Tacrolimus may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, The excretion of Ezetimibe can be decreased when combined with Tacrolimus.]
[L01XX24, pegaspargase, Tacrolimus may increase the immunosuppressive activities of Pegaspargase.]
[C04AE04, dihydroergocristine, The metabolism of Tacrolimus can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The serum concentration of Tacrolimus can be increased when it is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Tacrolimus may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Tacrolimus may increase the immunosuppressive activities of Lenalidomide.]
[J05AE08, atazanavir, The serum concentration of Tacrolimus can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Tacrolimus.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Tacrolimus.]
[V03AB04, pralidoxime, Tacrolimus may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D07AC18, prednicarbate, Tacrolimus may increase the immunosuppressive activities of Prednicarbate.]
[C08DB01, diltiazem, The serum concentration of Tacrolimus can be increased when it is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Tacrolimus may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The serum concentration of Tacrolimus can be increased when it is combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of renal failure can be increased when Propyphenazone is combined with Tacrolimus.]
[M01AB14, proglumetacin, The risk or severity of renal failure can be increased when Proglumetacin is combined with Tacrolimus.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Tacrolimus.]
[C05CA03, diosmin, The metabolism of Tacrolimus can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tacrolimus.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tacrolimus.]
[A03FA02, cisapride, The metabolism of Tacrolimus can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Tacrolimus.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus.]
[S01AX06, resorcinol, Tacrolimus may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tacrolimus.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Tacrolimus can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Tacrolimus can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tacrolimus can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Tacrolimus.]
[N05AX08, risperidone, The metabolism of Tacrolimus can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levocetirizine.]
[L04AA21, efalizumab, Tacrolimus may increase the immunosuppressive activities of Efalizumab.]
[N01BB09, ropivacaine, Tacrolimus may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Tacrolimus.]
[L01EX01, sunitinib, The serum concentration of Tacrolimus can be increased when it is combined with Sunitinib.]
[A04AD12, aprepitant, The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Tacrolimus.]
[L01XG01, bortezomib, Tacrolimus may increase the immunosuppressive activities of Bortezomib.]
[J05AE07, fosamprenavir, The metabolism of Tacrolimus can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Tacrolimus can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The risk or severity of renal failure can be increased when Ketorolac is combined with Tacrolimus.]
[C02KX02, ambrisentan, The metabolism of Tacrolimus can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Tacrolimus.]
[N02BA06, salsalate, The risk or severity of renal failure can be increased when Salsalate is combined with Tacrolimus.]
[R03AC12, salmeterol, The metabolism of Tacrolimus can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, Tacrolimus may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Tacrolimus may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Tacrolimus can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Tacrolimus may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Tacrolimus can be increased when it is combined with Doxorubicin.]
[J01AA02, doxycycline, Tacrolimus may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Tacrolimus.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Droperidol.]
[A08AA10, sibutramine, Tacrolimus may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Tacrolimus can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Tacrolimus.]
[A12CA02, sodium sulfate, Tacrolimus may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Spirapril.]
[R03DA01, dyphylline, Tacrolimus may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sultopride.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Tacrolimus.]
[V04CX07, edrophonium, Tacrolimus may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Tacrolimus.]
[H01AA01, corticotropin, Tacrolimus may increase the immunosuppressive activities of Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Temafloxacin.]
[L01AX03, temozolomide, Tacrolimus may increase the immunosuppressive activities of Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of renal failure can be increased when Tenoxicam is combined with Tacrolimus.]
[D01BA02, terbinafine, The metabolism of Tacrolimus can be increased when combined with Terbinafine.]
[G04BD05, terodiline, Terodiline may increase the immunosuppressive activities of Tacrolimus.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Tertatolol.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Tacrolimus.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Tacrolimus.]
[G01AF08, tioconazole, The serum concentration of Tacrolimus can be increased when it is combined with Tioconazole.]
[N05BA23, tofisopam, The serum concentration of Tacrolimus can be increased when it is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure can be increased when Tolfenamic acid is combined with Tacrolimus.]
[N06AG03, toloxatone, Tacrolimus may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tacrolimus.]
[N03AX11, topiramate, The metabolism of Tacrolimus can be increased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Toremifene.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Tacrolimus.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Tacrolimus.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Tacrolimus.]
[H02CA01, trilostane, Tacrolimus may increase the immunosuppressive activities of Trilostane.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Triptorelin.]
[L01AA07, trofosfamide, Tacrolimus may increase the immunosuppressive activities of Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Tacrolimus.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Tacrolimus.]
[L01CA04, vinorelbine, Tacrolimus may increase the immunosuppressive activities of Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Tacrolimus.]
[N06AX16, venlafaxine, Tacrolimus may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[S01GA03, xylometazoline, Xylometazoline may increase the immunosuppressive activities of Tacrolimus.]
[C08CA12, mepirodipine, The serum concentration of Tacrolimus can be increased when it is combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Tacrolimus can be increased when it is combined with Epinephrine.]
[L01DB03, epirubicin, Tacrolimus may increase the immunosuppressive activities of Epirubicin.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of renal failure can be increased when Zomepirac is combined with Tacrolimus.]
[N03AX15, zonisamide, Zonisamide may increase the immunosuppressive activities of Tacrolimus.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Tacrolimus.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Tacrolimus.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Tacrolimus.]
[L01XA02, carboplatin, Tacrolimus may increase the immunosuppressive activities of Carboplatin.]
[C02AC02, guanfacine, Tacrolimus may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Tacrolimus.]
[N02CA02, ergotamine, The serum concentration of Tacrolimus can be increased when it is combined with Ergotamine.]
[L03AX05, pidotimod, Tacrolimus may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Tacrolimus may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, The metabolism of Tacrolimus can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Tacrolimus can be decreased when combined with Estradiol.]
[L01XX11, estramustine, Tacrolimus may increase the immunosuppressive activities of Estramustine.]
[G03CA57, estrogens, conjugated (USP), The excretion of Conjugated estrogens can be decreased when combined with Tacrolimus.]
[J04AK02, ethambutol, The metabolism of Tacrolimus can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The serum concentration of Tacrolimus can be increased when it is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The serum concentration of Tacrolimus can be increased when it is combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Tacrolimus can be increased when it is combined with Fluvastatin.]
[V08CA03, gadodiamide, Tacrolimus may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[D07AC21, halobetasol, Tacrolimus may increase the immunosuppressive activities of Ulobetasol.]
[L02AA03, ethinyl estradiol, The metabolism of Tacrolimus can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ibutilide.]
[N03AD01, ethosuximide, Ethosuximide may increase the immunosuppressive activities of Tacrolimus.]
[M01AC06, meloxicam, The risk or severity of renal failure can be increased when Meloxicam is combined with Tacrolimus.]
[N01AX07, etomidate, Tacrolimus may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Tacrolimus can be increased when it is combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ajmaline.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Tacrolimus can be increased when it is combined with Astemizole.]
[R06AX12, terfenadine, The serum concentration of Tacrolimus can be increased when it is combined with Terfenadine.]
[P01AX07, trimetrexate, Tacrolimus may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Tacrolimus may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The serum concentration of Tacrolimus can be increased when it is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrolimus.]
[L04AA02, muromonab-CD3, Tacrolimus may increase the immunosuppressive activities of Muromonab.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Tacrolimus.]
[M01CB01, gold sodium thiomalate, Tacrolimus may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Tacrolimus may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Tacrolimus may increase the immunosuppressive activities of Dexrazoxane.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Famotidine.]
[A16AA01, levocarnitine, Tacrolimus may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Tacrolimus can be decreased when combined with Albendazole.]
[C08CA02, felodipine, Felodipine may increase the immunosuppressive activities of Tacrolimus.]
[C08EA01, fendiline, Fendiline may increase the immunosuppressive activities of Tacrolimus.]
[M01AE04, fenoprofen, The risk or severity of renal failure can be increased when Fenoprofen is combined with Tacrolimus.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Tacrolimus.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Tacrolimus.]
[L01BB06, clofarabine, Tacrolimus may increase the immunosuppressive activities of Clofarabine.]
[L04AA40, cladribine, Tacrolimus may increase the immunosuppressive activities of Cladribine.]
[N07AX03, cevimeline, Tacrolimus may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Tacrolimus may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of renal failure can be increased when Floctafenine is combined with Tacrolimus.]
[J01CF05, floxacillin, The metabolism of Tacrolimus can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Tacrolimus can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Tacrolimus may increase the immunosuppressive activities of Flucytosine.]
[H02AA02, fludrocortisone, Tacrolimus may increase the immunosuppressive activities of Fludrocortisone.]
[V03AB25, flumazenil, Tacrolimus may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, Tacrolimus may increase the immunosuppressive activities of Flumethasone.]
[N07CA03, flunarizine, Flunarizine may increase the immunosuppressive activities of Tacrolimus.]
[D07AC08, fluocinonide, Tacrolimus may increase the immunosuppressive activities of Fluocinonide.]
[H02AB03, fluocortolone, Tacrolimus may increase the immunosuppressive activities of Fluocortolone.]
[V03AZ01, ethanol, Ethanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01BC09, floxuridine, Tacrolimus may increase the immunosuppressive activities of Floxuridine.]
[S01CB05, fluorometholone, Tacrolimus may increase the immunosuppressive activities of Fluorometholone.]
[L01BC02, fluorouracil, Tacrolimus may increase the immunosuppressive activities of Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Tacrolimus.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tacrolimus.]
[D07AC07, flurandrenolide, Tacrolimus may increase the immunosuppressive activities of Flurandrenolide.]
[N05CD01, flurazepam, Tacrolimus may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of renal failure can be increased when Flurbiprofen is combined with Tacrolimus.]
[N05AG01, fluspirilene, Fluspirilene may increase the immunosuppressive activities of Tacrolimus.]
[L02BB01, flutamide, The metabolism of Tacrolimus can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Tacrolimus may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Tacrolimus may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Tacrolimus.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Tacrolimus.]
[J05AE10, darunavir, The serum concentration of Tacrolimus can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Furosemide is combined with Tacrolimus.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Tacrolimus.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tacrolimus.]
[C08DA02, gallopamil, Gallopamil may increase the immunosuppressive activities of Tacrolimus.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ganciclovir.]
[N03AA04, barbexaclone, The metabolism of Tacrolimus can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, Tacrolimus may increase the nephrotoxic activities of Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Degarelix.]
[L01EA02, dasatinib, The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Tacrolimus can be increased when it is combined with Cabergoline.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Tacrolimus.]
[J05AG04, etravirine, The metabolism of Tacrolimus can be increased when combined with Etravirine.]
[N03AD03, methsuximide, Methsuximide may increase the immunosuppressive activities of Tacrolimus.]
[N01AH02, alfentanil, The metabolism of Tacrolimus can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Tacrolimus can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The serum concentration of Tacrolimus can be increased when it is combined with Glyburide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tacrolimus.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Tacrolimus.]
[N05CM18, dexmedetomidine, Tacrolimus may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Tacrolimus.]
[C02CA04, doxazosin, The metabolism of Tacrolimus can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Tacrolimus can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tacrolimus.]
[M01CB04, aurothioglucose, Tacrolimus may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Tacrolimus may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Tacrolimus.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tacrolimus.]
[D01BA01, griseofulvin, The metabolism of Tacrolimus can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Tacrolimus may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Tacrolimus can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, Tacrolimus may increase the immunosuppressive activities of Halcinonide.]
[N05AD01, haloperidol, The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Histrelin.]
[N05AH04, quetiapine, The metabolism of Tacrolimus can be decreased when combined with Quetiapine.]
[N06BX13, idebenone, Tacrolimus may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Tacrolimus.]
[L01CE02, irinotecan, Tacrolimus may increase the immunosuppressive activities of Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Tacrolimus.]
[C09CA01, losartan, The serum concentration of Tacrolimus can be increased when it is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Tacrolimus can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of renal failure can be increased when Mesalazine is combined with Tacrolimus.]
[C01CE02, milrinone, Tacrolimus may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, Tacrolimus may increase the immunosuppressive activities of Altretamine.]
[J05AG01, nevirapine, The metabolism of Tacrolimus can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The serum concentration of Tacrolimus can be increased when it is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure can be increased when Nimesulide is combined with Tacrolimus.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Tacrolimus.]
[C02DB02, hydralazine, The serum concentration of Tacrolimus can be increased when it is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone.]
[D07AC16, hydrocortisone aceponate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone aceponate.]
[D07AB11, hydrocortisone probutate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone probutate.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Tacrolimus.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Tacrolimus.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Tacrolimus.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Tacrolimus.]
[V03AB33, hydroxocobalamin, Tacrolimus may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Tacrolimus may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, Tacrolimus may increase the immunosuppressive activities of Hydroxychloroquine.]
[B05AA07, hetastarch, Tacrolimus may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, Tacrolimus may increase the immunosuppressive activities of Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Tacrolimus can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, Tacrolimus may increase the immunosuppressive activities of Rimexolone.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of renal failure can be increased when Ibuprofen is combined with Tacrolimus.]
[B05XA08, sodium acetate, Tacrolimus may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Tacrolimus.]
[L01DB06, idarubicin, Tacrolimus may increase the immunosuppressive activities of Idarubicin.]
[L01AA06, ifosfamide, The serum concentration of Tacrolimus can be increased when it is combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Tacrolimus.]
[L01CD01, paclitaxel, Tacrolimus may increase the immunosuppressive activities of Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Terlipressin.]
[R01AD07, tixocortol, Tacrolimus may increase the immunosuppressive activities of Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Tacrolimus.]
[L01CE01, topotecan, The serum concentration of Tacrolimus can be increased when it is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Tacrolimus.]
[S01BC01, indomethacin, Tacrolimus may increase the immunosuppressive activities of Indomethacin.]
[A11HA07, inositol, Tacrolimus may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2b.]
[N06AX17, milnacipran, The serum concentration of Tacrolimus can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, Tacrolimus may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, Tacrolimus may increase the immunosuppressive activities of Eculizumab.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Tacrolimus.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Tacrolimus.]
[N05CH02, ramelteon, Tacrolimus may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Tacrolimus.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tacrolimus.]
[C10AA06, cerivastatin, The serum concentration of Tacrolimus can be increased when it is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, Tacrolimus may increase the immunosuppressive activities of Interferon alfacon-1.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Tacrolimus.]
[D06BB10, imiquimod, Tacrolimus may increase the immunosuppressive activities of Imiquimod.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Tacrolimus.]
[J04AC01, isoniazid, The serum concentration of Tacrolimus can be increased when it is combined with Isoniazid.]
[J05AX05, inosine pranobex, Tacrolimus may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Tacrolimus.]
[C01DA14, isosorbide mononitrate, Tacrolimus may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Tacrolimus.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Tacrolimus.]
[J01FA07, josamycin, The serum concentration of Tacrolimus can be increased when it is combined with Josamycin.]
[S01AA24, kanamycin, Tacrolimus may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Tacrolimus.]
[L04AC07, tocilizumab, Tacrolimus may increase the immunosuppressive activities of Tocilizumab.]
[N01AX03, ketamine, Tacrolimus may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Tacrolimus.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Tacrolimus.]
[J02AB02, ketoconazole, The serum concentration of Tacrolimus can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Tacrolimus can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Tacrolimus.]
[M02AA10, ketoprofen, The risk or severity of renal failure can be increased when Ketoprofen is combined with Tacrolimus.]
[V03AC03, deferasirox, The metabolism of Tacrolimus can be increased when combined with Deferasirox.]
[L04AA24, abatacept, Tacrolimus may increase the immunosuppressive activities of Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure can be increased when Tiaprofenic acid is combined with Tacrolimus.]
[C07AG01, labetalol, The risk or severity of hyperkalemia can be increased when Labetalol is combined with Tacrolimus.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amantadine.]
[A06AX03, lubiprostone, Tacrolimus may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Tacrolimus can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Etacrynic acid.]
[L01DC03, mitomycin, Tacrolimus may increase the immunosuppressive activities of Mitomycin.]
[G03AD01, levonorgestrel, The metabolism of Tacrolimus can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Tacrolimus can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, Lidoflazine may increase the immunosuppressive activities of Tacrolimus.]
[S01AA21, amikacin, Tacrolimus may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Tacrolimus can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Tacrolimus.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Tacrolimus.]
[L01AD02, lomustine, Tacrolimus may increase the immunosuppressive activities of Lomustine.]
[A07DA03, loperamide, Loperamide may increase the immunosuppressive activities of Tacrolimus.]
[N05BA06, lorazepam, Tacrolimus may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Tacrolimus.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Tacrolimus may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Tacrolimus may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the immunosuppressive activities of Tacrolimus.]
[L01BA05, pralatrexate, Tacrolimus may increase the immunosuppressive activities of Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Tacrolimus can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tacrolimus.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Maprotiline.]
[C02BB01, mecamylamine, Tacrolimus may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[L01AA05, mechlorethamine, Tacrolimus may increase the immunosuppressive activities of Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure can be increased when Meclofenamic acid is combined with Tacrolimus.]
[C01AA08, medigoxin, Tacrolimus may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The serum concentration of Tacrolimus can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Dalteparin.]
[L01AA03, melphalan, Tacrolimus may increase the immunosuppressive activities of Melphalan.]
[N06DX01, memantine, Tacrolimus may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Tacrolimus can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Tacrolimus can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Tacrolimus may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Tacrolimus may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Tacrolimus can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Tacrolimus may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Tacrolimus can be decreased when combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dolasetron.]
[H01CB03, lanreotide, The serum concentration of Tacrolimus can be increased when it is combined with Lanreotide.]
[N07BC02, methadone, The serum concentration of Tacrolimus can be increased when it is combined with Methadone.]
[N06BA03, methamphetamine, Tacrolimus may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Tacrolimus.]
[H03BB02, methimazole, The serum concentration of Tacrolimus can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, Tacrolimus may increase the immunosuppressive activities of Pemetrexed.]
[A11HA02, pyridoxine, Tacrolimus may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[N02BG08, ziconotide, Ziconotide may increase the immunosuppressive activities of Tacrolimus.]
[L04AX03, methotrexate, Tacrolimus may increase the immunosuppressive activities of Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Tacrolimus may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tacrolimus.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Methyldopa.]
[V04CG05, methylene blue, The serum concentration of Tacrolimus can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The serum concentration of Tacrolimus can be increased when it is combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Tacrolimus.]
[H02AB04, methylprednisolone, Tacrolimus may increase the immunosuppressive activities of Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Tacrolimus can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Tacrolimus may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Tacrolimus can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Metoclopramide.]
[C03BA08, metolazone, Tacrolimus may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, The risk or severity of hyperkalemia can be increased when Metoprolol is combined with Tacrolimus.]
[P01AB01, metronidazole, The serum concentration of Tacrolimus can be increased when it is combined with Metronidazole.]
[V04CD01, metyrapone, The serum concentration of Tacrolimus can be increased when it is combined with Metyrapone.]
[S02AA13, miconazole, The serum concentration of Tacrolimus can be increased when it is combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of renal failure can be increased when Aminophenazone is combined with Tacrolimus.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Tacrolimus.]
[G03XB01, mifepristone, The serum concentration of Tacrolimus can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Tinzaparin.]
[J05AH01, zanamivir, Tacrolimus may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Tacrolimus.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Minocycline.]
[J01FA11, miocamycin, The serum concentration of Tacrolimus can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Tacrolimus can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Tacrolimus may increase the immunosuppressive activities of Mitoxantrone.]
[L03AC01, aldesleukin, The serum concentration of Tacrolimus can be increased when it is combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Tacrolimus can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Tacrolimus can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Tacrolimus.]
[A04AA05, palonosetron, Tacrolimus may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Tacrolimus may increase the immunosuppressive activities of Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Ammonium chloride.]
[L04AA52, ofatumumab, Tacrolimus may increase the immunosuppressive activities of Ofatumumab.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.]
[L04AA06, mycophenolic acid, Tacrolimus may increase the immunosuppressive activities of Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Tacrolimus can be increased when combined with Amobarbital.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Tacrolimus.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Tacrolimus.]
[G03XC01, raloxifene, The serum concentration of Tacrolimus can be increased when it is combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Tacrolimus.]
[N03AB05, fosphenytoin, The serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, Tacrolimus may increase the immunosuppressive activities of Interferon beta-1b.]
[C07AA12, nadolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nadolol.]
[J01CA04, amoxicillin, Tacrolimus may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The metabolism of Tacrolimus can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The serum concentration of Tacrolimus can be increased when it is combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Tacrolimus.]
[L04AC03, anakinra, Tacrolimus may increase the immunosuppressive activities of Anakinra.]
[N06BA01, amphetamine, Tacrolimus may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of renal failure can be increased when Naproxen is combined with Tacrolimus.]
[A10BG01, troglitazone, The metabolism of Tacrolimus can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, Tacrolimus may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Tacrolimus may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, The serum concentration of Tacrolimus can be increased when it is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Neomycin.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Tacrolimus.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Tacrolimus.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tacrolimus.]
[S01AA19, ampicillin, Tacrolimus may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Tacrolimus may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Tacrolimus may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The serum concentration of Tacrolimus can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Tacrolimus.]
[C01CE01, inamrinone, Tacrolimus may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, Tacrolimus may increase the immunosuppressive activities of Amsacrine.]
[C10AD02, niacin, The metabolism of Tacrolimus can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.]
[C08CA05, nifedipine, Nifedipine may increase the immunosuppressive activities of Tacrolimus.]
[M02AA17, niflumic acid, The risk or severity of renal failure can be increased when Niflumic acid is combined with Tacrolimus.]
[C08CA06, nimodipine, Nimodipine may increase the immunosuppressive activities of Tacrolimus.]
[C08CA07, nisoldipine, Nisoldipine may increase the immunosuppressive activities of Tacrolimus.]
[C08CA08, nitrendipine, Nitrendipine may increase the immunosuppressive activities of Tacrolimus.]
[R07AX01, nitric oxide, The serum concentration of Tacrolimus can be increased when it is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Tacrolimus.]
[N05CF03, zaleplon, The metabolism of Tacrolimus can be decreased when combined with Zaleplon.]
[N04BC05, pramipexole, Tacrolimus may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Tacrolimus may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[G03DC02, norethindrone, The metabolism of Tacrolimus can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The serum concentration of Tacrolimus can be increased when it is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Tacrolimus can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Tacrolimus.]
[R05DA07, noscapine, The serum concentration of Tacrolimus can be increased when it is combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Tacrolimus.]
[G02CA02, nylidrin, Nylidrin may increase the immunosuppressive activities of Tacrolimus.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Tacrolimus can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, Tacrolimus may increase the immunosuppressive activities of Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.]
[N02AA02, opium, Tacrolimus may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Tacrolimus.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Tacrolimus.]
[G04CA02, tamsulosin, Tacrolimus may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Tacrolimus.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Zoledronic acid.]
[J01CF04, oxacillin, Tacrolimus may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Tacrolimus may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Tacrolimus can be decreased when combined with Oxycodone.]
[A14AA05, oxymetholone, The serum concentration of Tacrolimus can be increased when it is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure can be increased when Oxyphenbutazone is combined with Tacrolimus.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Danaparoid.]
[J04AB30, capreomycin, Tacrolimus may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Tacrolimus can be increased when it is combined with Paramethasone.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Paromomycin.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Tacrolimus.]
[G04BD11, fesoterodine, Tacrolimus may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Penbutolol.]
[N05AG03, penfluridol, Penfluridol may increase the immunosuppressive activities of Tacrolimus.]
[M01CC01, penicillamine, Tacrolimus may increase the immunosuppressive activities of Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Tacrolimus.]
[J01CE09, penicillin G procaine, Tacrolimus may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.]
[N05CA01, pentobarbital, The metabolism of Tacrolimus can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Tacrolimus may increase the immunosuppressive activities of Pentostatin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Tacrolimus.]
[C08EX02, perhexiline, Perhexiline may increase the immunosuppressive activities of Tacrolimus.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tacrolimus.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Phenazopyridine.]
[N06AF03, phenelzine, The serum concentration of Tacrolimus can be increased when it is combined with Phenelzine.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Tacrolimus.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Tacrolimus.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Tacrolimus can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Tacrolimus.]
[V03AB36, phentolamine, Tacrolimus may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of renal failure can be increased when Phenylbutazone is combined with Tacrolimus.]
[A02BC06, dexlansoprazole, The metabolism of Tacrolimus can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, Tacrolimus may increase the immunosuppressive activities of Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levofloxacin.]
[L02BB03, bicalutamide, The serum concentration of Tacrolimus can be increased when it is combined with Bicalutamide.]
[B02BA01, vitamin K1, Tacrolimus may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tacrolimus.]
[C08CX01, mibefradil, The serum concentration of Tacrolimus can be increased when it is combined with Mibefradil.]
[S01EB01, pilocarpine, The serum concentration of Tacrolimus can be increased when it is combined with Pilocarpine.]
[N05AG02, pimozide, The serum concentration of Tacrolimus can be increased when it is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Tacrolimus.]
[J01CA12, piperacillin, Tacrolimus may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Tacrolimus can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Tacrolimus may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of renal failure can be increased when Piroxicam is combined with Tacrolimus.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefditoren.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Grepafloxacin.]
[J05AG02, delavirdine, The serum concentration of Tacrolimus can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The serum concentration of Tacrolimus can be increased when it is combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Tacrolimus.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Tacrolimus.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tacrolimus.]
[L04AC08, canakinumab, Tacrolimus may increase the immunosuppressive activities of Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Tacrolimus.]
[J05AE03, ritonavir, The serum concentration of Tacrolimus can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Tacrolimus can be decreased when combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Tacrolimus.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Tacrolimus.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Tacrolimus.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Pitavastatin.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Tacrolimus can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, Tacrolimus may increase the immunosuppressive activities of Prednisolone.]
[H02AB07, prednisone, Tacrolimus may increase the immunosuppressive activities of Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Antazoline.]
[C01DX02, prenylamine, Prenylamine may increase the immunosuppressive activities of Tacrolimus.]
[P01BA03, primaquine, The serum concentration of Tacrolimus can be increased when it is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Tacrolimus can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Tacrolimus can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Probucol.]
[C01BA02, procainamide, Tacrolimus may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XB01, procarbazine, Tacrolimus may increase the immunosuppressive activities of Procarbazine.]
[C10AB05, fenofibrate, Tacrolimus may increase the nephrotoxic activities of Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Tacrolimus can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Propafenone.]
[A03AB05, propantheline, Tacrolimus may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Tacrolimus.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Tacrolimus.]
[N01AX10, propofol, The serum concentration of Tacrolimus can be increased when it is combined with Propofol.]
[N02AC04, propoxyphene, The serum concentration of Tacrolimus can be increased when it is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Tacrolimus can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, Tacrolimus may increase the immunosuppressive activities of Propylthiouracil.]
[N02CC04, rizatriptan, Tacrolimus may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tacrolimus.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Tacrolimus.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Tacrolimus.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Tacrolimus.]
[N07XX07, dalfampridine, Tacrolimus may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Tacrolimus may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Tacrolimus may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Tacrolimus.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Tacrolimus.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Tacrolimus can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Tacrolimus can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Tacrolimus can be increased when it is combined with Quinine.]
[D07AC10, diflorasone, Tacrolimus may increase the immunosuppressive activities of Diflorasone.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Tacrolimus.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Rescinnamine.]
[C02AA02, reserpine, The metabolism of Tacrolimus can be increased when combined with Reserpine.]
[J05AP01, ribavirin, Tacrolimus may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Tacrolimus can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Roxithromycin.]
[C05CA01, rutin, The serum concentration of Tacrolimus can be increased when it is combined with Rutin.]
[N02BA05, salicylamide, The risk or severity of renal failure can be increased when Salicylamide is combined with Tacrolimus.]
[A07EC01, sulfasalazine, Tacrolimus may increase the immunosuppressive activities of Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of renal failure can be increased when Salicylic acid is combined with Tacrolimus.]
[N05CA06, secobarbital, The metabolism of Tacrolimus can be increased when combined with Secobarbital.]
[L01FA03, obinutuzumab, Tacrolimus may increase the immunosuppressive activities of Obinutuzumab.]
[J01GB08, sisomicin, Tacrolimus may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Tacrolimus may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.]
[H01CB01, somatostatin, The serum concentration of Tacrolimus can be increased when it is combined with Somatostatin.]
[V04CC01, sorbitol, Tacrolimus may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sotalol.]
[L01CD04, cabazitaxel, Tacrolimus may increase the immunosuppressive activities of Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Etidronic acid.]
[D07AB02, hydrocortisone butyrate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone butyrate.]
[D10AX03, azelaic acid, Tacrolimus may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[S02DA03, antipyrine, The risk or severity of renal failure can be increased when Antipyrine is combined with Tacrolimus.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Tacrolimus.]
[J01GA01, streptomycin, Tacrolimus may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, Tacrolimus may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).]
[L01AD04, streptozocin, Tacrolimus may increase the immunosuppressive activities of Streptozocin.]
[L04AA27, fingolimod, Tacrolimus may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tacrolimus.]
[A02BX02, sucralfate, Tacrolimus may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Tacrolimus may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Tacrolimus.]
[J01EC01, sulfamethoxazole, The serum concentration of Tacrolimus can be increased when it is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Tacrolimus can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Tacrolimus.]
[M01AB02, sulindac, The risk or severity of renal failure can be increased when Sulindac is combined with Tacrolimus.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Tacrolimus.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Tacrolimus.]
[M01AX04, apazone, The risk or severity of renal failure can be increased when Azapropazone is combined with Tacrolimus.]
[L01BB02, mercaptopurine, Tacrolimus may increase the immunosuppressive activities of Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Tacrolimus.]
[L02BA01, tamoxifen, The serum concentration of Tacrolimus can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Tacrolimus may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The serum concentration of Tacrolimus can be increased when it is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Tacrolimus.]
[G03BA03, testosterone, The metabolism of Tacrolimus can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Tetrabenazine.]
[S03AA02, tetracycline, The serum concentration of Tacrolimus can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Tacrolimus.]
[N04BC07, apomorphine, The metabolism of Tacrolimus can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, Tacrolimus may increase the immunosuppressive activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Tacrolimus.]
[P02CA02, thiabendazole, Tacrolimus may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, Tacrolimus may increase the immunosuppressive activities of Eribulin.]
[R06AD03, thiethylperazine, Tacrolimus may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, Tacrolimus may increase the immunosuppressive activities of Thiotepa.]
[L01BB03, thioguanine, Tacrolimus may increase the immunosuppressive activities of Tioguanine.]
[N05CA19, thiopental, The serum concentration of Tacrolimus can be increased when it is combined with Thiopental.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Thiothixene.]
[G04BE06, moxisylyte, Tacrolimus may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Tacrolimus may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Tacrolimus.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Tacrolimus.]
[P01AB02, tinidazole, Tacrolimus may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Tacrolimus may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Tacrolimus.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus.]
[M02AA21, tolmetin, The risk or severity of renal failure can be increased when Tolmetin is combined with Tacrolimus.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Tacrolimus.]
[N06AF04, tranylcypromine, The serum concentration of Tacrolimus can be increased when it is combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Tacrolimus.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tacrolimus.]
[L01XF01, tretinoin, Tacrolimus may increase the immunosuppressive activities of Tretinoin.]
[S01BA05, triamcinolone, Tacrolimus may increase the immunosuppressive activities of Triamcinolone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.]
[N05CD05, triazolam, The metabolism of Tacrolimus can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Tacrolimus.]
[A16AX12, trientine, Tacrolimus may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Tacrolimus may increase the immunosuppressive activities of Trifluridine.]
[S01BA09, clobetasone, Tacrolimus may increase the immunosuppressive activities of Clobetasone.]
[S01BA10, alclometasone, Tacrolimus may increase the immunosuppressive activities of Alclometasone.]
[D07AC02, fluclorolone, Tacrolimus may increase the immunosuppressive activities of Fluclorolone.]
[R03BA07, mometasone, Tacrolimus may increase the immunosuppressive activities of Mometasone.]
[A03AA05, trimebutine, Trimebutine may increase the immunosuppressive activities of Tacrolimus.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the immunosuppressive activities of Tacrolimus.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Tacrolimus.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Tacrolimus.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Tacrolimus.]
[J01FA08, troleandomycin, The serum concentration of Tacrolimus can be increased when it is combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Tacrolimus.]
[L04AA26, belimumab, Tacrolimus may increase the immunosuppressive activities of Belimumab.]
[L01FX04, ipilimumab, Tacrolimus may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Tacrolimus.]
[R02AA14, oxyquinoline, Tacrolimus may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Tacrolimus can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Tacrolimus can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Tacrolimus can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Tacrolimus can be increased when it is combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Tacrolimus.]
[S01AA28, vancomycin, Tacrolimus may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, Tacrolimus may increase the immunosuppressive activities of Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ezogabine.]
[B01AF01, rivaroxaban, The metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Tacrolimus.]
[B01AC24, ticagrelor, The serum concentration of Tacrolimus can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Tacrolimus can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The serum concentration of Tacrolimus can be increased when it is combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Tacrolimus can be increased when it is combined with Vinblastine.]
[L01CA02, vincristine, Tacrolimus may increase the immunosuppressive activities of Vincristine.]
[L01CA03, vindesine, Tacrolimus may increase the immunosuppressive activities of Vindesine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tacrolimus.]
[A11HA03, vitamin E, The metabolism of Tacrolimus can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Tacrolimus.]
[J05AF01, zidovudine, Tacrolimus may increase the immunosuppressive activities of Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Tacrolimus can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Tacrolimus can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tacrolimus.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Tacrolimus.]
[L01FX05, brentuximab vedotin, The serum concentration of Tacrolimus can be increased when it is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Tiludronic acid.]
[B06AC02, icatibant, Tacrolimus may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Tacrolimus can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.]
[R03DC01, zafirlukast, The serum concentration of Tacrolimus can be increased when it is combined with Zafirlukast.]
[A02BC04, rabeprazole, The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Tacrolimus can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Tacrolimus may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.]
[N02BA01, aspirin, The risk or severity of renal failure can be increased when Acetylsalicylic acid is combined with Tacrolimus.]
[L01EJ01, ruxolitinib, Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Tolterodine.]
[J01DH04, doripenem, Tacrolimus may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Atenolol is combined with Tacrolimus.]
[L03AB11, peginterferon alfa-2a, Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2a.]
[L01FA01, rituximab, Tacrolimus may increase the immunosuppressive activities of Rituximab.]
[J02AC03, voriconazole, The serum concentration of Tacrolimus can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Atropine.]
[M01CB03, auranofin, Tacrolimus may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.]
[R07AX02, ivacaftor, The serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, Tacrolimus may increase the immunosuppressive activities of Prednylidene.]
[B03XA04, peginesatide, Tacrolimus may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Tacrolimus may increase the immunosuppressive activities of Azacitidine.]
[L04AX01, azathioprine, Tacrolimus may increase the immunosuppressive activities of Azathioprine.]
[L01BC05, gemcitabine, Tacrolimus may increase the immunosuppressive activities of Gemcitabine.]
[J01DF01, aztreonam, Tacrolimus may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Tacrolimus.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tacrolimus.]
[M03BX01, baclofen, Tacrolimus may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Tacrolimus.]
[L01FX02, gemtuzumab ozogamicin, Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Tacrolimus may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Tacrolimus.]
[L01XG02, carfilzomib, Tacrolimus may increase the immunosuppressive activities of Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Tacrolimus can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Tacrolimus can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus.]
[L04AA31, teriflunomide, Tacrolimus may increase the immunosuppressive activities of Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Tacrolimus.]
[L04AA22, abetimus, Tacrolimus may increase the immunosuppressive activities of Abetimus.]
[H02AA01, aldosterone, Tacrolimus may increase the immunosuppressive activities of Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Tacrolimus can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Tacrolimus can be increased when combined with Barbital.]
[D02BA02, octinoxate, Tacrolimus may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The serum concentration of Tacrolimus can be increased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, Tacrolimus may increase the immunosuppressive activities of Bendamustine.]
[N04BD02, rasagiline, Tacrolimus may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, Lercanidipine may increase the immunosuppressive activities of Tacrolimus.]
[N03AX22, perampanel, The metabolism of Tacrolimus can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Tacrolimus.]
[V09IX04, fluorodeoxyglucose F18, Tacrolimus may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The serum concentration of Tacrolimus can be increased when it is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Tacrolimus can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Tacrolimus may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, Tacrolimus may increase the immunosuppressive activities of Ponatinib.]
[B01AF02, apixaban, The metabolism of Tacrolimus can be decreased when combined with Apixaban.]
[A16AX08, teduglutide, Tacrolimus may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Tacrolimus.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Bedaquiline.]
[C04AX11, bencyclane, Bencyclane may increase the immunosuppressive activities of Tacrolimus.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Tacrolimus can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Tacrolimus.]
[L04AX06, pomalidomide, Tacrolimus may increase the immunosuppressive activities of Pomalidomide.]
[N02BA10, benorilate, The risk or severity of renal failure can be increased when Benorilate is combined with Tacrolimus.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.]
[L04AX07, dimethyl fumarate, Tacrolimus may increase the immunosuppressive activities of Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Tacrolimus.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Tacrolimus.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Tacrolimus.]
[J02AX04, caspofungin, The serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin.]
[L03AA12, ancestim, Tacrolimus may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of renal failure can be increased when Celecoxib is combined with Tacrolimus.]
[L04AA18, everolimus, The serum concentration of Tacrolimus can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Tacrolimus.]
[L01EC02, dabrafenib, The serum concentration of Tacrolimus can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of renal failure can be increased when Benzydamine is combined with Tacrolimus.]
[L01EE01, trametinib, Tacrolimus may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Tacrolimus may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Tacrolimus.]
[N06AX28, levomilnacipran, Tacrolimus may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Tacrolimus.]
[C08EA02, bepridil, Bepridil may increase the immunosuppressive activities of Tacrolimus.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Tacrolimus.]
[L03AA14, lipegfilgrastim, Tacrolimus may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Tacrolimus.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Tacrolimus.]
[C02KX04, macitentan, Tacrolimus may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Tacrolimus.]
[N06AX26, vortioxetine, The metabolism of Tacrolimus can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, Tacrolimus may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Tacrolimus can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Tacrolimus can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Tacrolimus.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tacrolimus.]
[C01CA27, droxidopa, Tacrolimus may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tacrolimus can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Tacrolimus can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Tacrolimus may increase the immunosuppressive activities of Apremilast.]
[L02BG02, formestane, The metabolism of Tacrolimus can be increased when combined with Formestane.]
[S03BA03, betamethasone, Tacrolimus may increase the immunosuppressive activities of Betamethasone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tacrolimus.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Tacrolimus.]
[V03AB34, fomepizole, Tacrolimus may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, Tacrolimus may increase the nephrotoxic activities of Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Tacrolimus.]
[L04AC11, siltuximab, The serum concentration of Tacrolimus can be increased when it is combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Tacrolimus can be increased when it is combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Tacrolimus can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, Tacrolimus may increase the immunosuppressive activities of Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tacrolimus.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Tacrolimus.]
[L01XH04, belinostat, Tacrolimus may increase the immunosuppressive activities of Belinostat.]
[L01EM01, idelalisib, The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, Tacrolimus may increase the immunosuppressive activities of Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Tacrolimus may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Tacrolimus may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Tacrolimus can be decreased when combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Tacrolimus.]
[J01XA05, oritavancin, The metabolism of Tacrolimus can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Dihydrostreptomycin.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tacrolimus.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Tacrolimus.]
[L01BC08, decitabine, Tacrolimus may increase the immunosuppressive activities of Decitabine.]
[L04AX05, pirfenidone, Tacrolimus may increase the immunosuppressive activities of Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Tacrolimus can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Tacrolimus may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, Tacrolimus may increase the immunosuppressive activities of Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Tacrolimus.]
[L01XK01, olaparib, The serum concentration of Tacrolimus can be increased when it is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Tacrolimus.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Tacrolimus.]
[N06AX11, mirtazapine, The serum concentration of Tacrolimus can be increased when it is combined with Mirtazapine.]
[L04AC10, secukinumab, Tacrolimus may increase the immunosuppressive activities of Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Tacrolimus.]
[L01XH03, panobinostat, Tacrolimus may increase the immunosuppressive activities of Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Tacrolimus can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The serum concentration of Tacrolimus can be increased when it is combined with Acetaminophen.]
[L01DC01, bleomycin, Tacrolimus may increase the immunosuppressive activities of Bleomycin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Tacrolimus.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Tacrolimus.]
[J05AP06, asunaprevir, The metabolism of Tacrolimus can be increased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Tacrolimus.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Tacrolimus.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Tacrolimus.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Tacrolimus.]
[M02AA25, aceclofenac, The risk or severity of renal failure can be increased when Aceclofenac is combined with Tacrolimus.]
[M01AB11, acemetacin, The risk or severity of renal failure can be increased when Acemetacin is combined with Tacrolimus.]
[S01EC01, acetazolamide, The serum concentration of Tacrolimus can be increased when it is combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Tacrolimus.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Acipimox.]
[A02BC03, lansoprazole, The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.]
[V03AB37, idarucizumab, Tacrolimus may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, Tacrolimus may increase the immunosuppressive activities of Trabectedin.]
[R03DX09, mepolizumab, Tacrolimus may increase the immunosuppressive activities of Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Tacrolimus can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Tacrolimus.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tacrolimus.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Tacrolimus.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Tacrolimus.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Tacrolimus.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Tacrolimus.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Tacrolimus.]
[M04AB05, lesinurad, The metabolism of Tacrolimus can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Tacrolimus can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Tacrolimus.]
[N05CA05, aprobarbital, The metabolism of Tacrolimus can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of renal failure can be increased when Alminoprofen is combined with Tacrolimus.]
[N03AX23, brivaracetam, Tacrolimus may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L04AC13, ixekizumab, Tacrolimus may increase the immunosuppressive activities of Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Tacrolimus can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Tacrolimus may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The serum concentration of Tacrolimus can be increased when it is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Tacrolimus may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[D07AC11, amcinonide, Tacrolimus may increase the immunosuppressive activities of Amcinonide.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tacrolimus.]
[C08CA01, amlodipine, Amlodipine may increase the immunosuppressive activities of Tacrolimus.]
[N05AX17, pimavanserin, The metabolism of Tacrolimus can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Bumetanide.]
[N01BB01, bupivacaine, Tacrolimus may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Bupranolol.]
[N07BC01, buprenorphine, The serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Tacrolimus can be decreased when combined with Buspirone.]
[L01AB01, busulfan, Tacrolimus may increase the immunosuppressive activities of Busulfan.]
[L01XX27, arsenic trioxide, Tacrolimus may increase the immunosuppressive activities of Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Tacrolimus can be decreased when combined with Artemether.]
[M02AA03, clofezone, The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Tacrolimus.]
[S01GX07, azelastine, The serum concentration of Tacrolimus can be increased when it is combined with Azelastine.]
[L01XK03, rucaparib, The serum concentration of Tacrolimus can be increased when it is combined with Rucaparib.]
[S01AA26, azithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin.]
[L04AC12, brodalumab, Tacrolimus may increase the immunosuppressive activities of Brodalumab.]
[L01EF02, ribociclib, The serum concentration of Tacrolimus can be increased when it is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of renal failure can be increased when Balsalazide is combined with Tacrolimus.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Tacrolimus.]
[A06AH05, naldemedine, Tacrolimus may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Tacrolimus can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Tacrolimus.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Tacrolimus.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Tacrolimus.]
[D05AX03, calcitriol, The metabolism of Tacrolimus can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Tacrolimus may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, Tacrolimus may increase the immunosuppressive activities of Daclizumab.]
[J01XX08, linezolid, Tacrolimus may increase the immunosuppressive activities of Linezolid.]
[J05AF06, abacavir, Tacrolimus may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Tacrolimus can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Tacrolimus can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, Tacrolimus may increase the immunosuppressive activities of Infliximab.]
[L01EX10, midostaurin, The serum concentration of Tacrolimus can be increased when it is combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Tacrolimus.]
[L04AC14, sarilumab, The serum concentration of Tacrolimus can be increased when it is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Tacrolimus.]
[L04AC16, guselkumab, Tacrolimus may increase the immunosuppressive activities of Guselkumab.]
[D01AC10, bifonazole, The serum concentration of Tacrolimus can be increased when it is combined with Bifonazole.]
[P03AC02, bioallethrin, Bioallethrin may increase the immunosuppressive activities of Tacrolimus.]
[L01BC06, capecitabine, Tacrolimus may increase the immunosuppressive activities of Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Tacrolimus can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Tacrolimus.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tacrolimus.]
[L01XH01, vorinostat, Tacrolimus may increase the immunosuppressive activities of Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Tacrolimus.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Tacrolimus.]
[J05AG03, efavirenz, The serum concentration of Tacrolimus can be increased when it is combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefprozil.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Bopindolol.]
[L04AC02, basiliximab, Tacrolimus may increase the immunosuppressive activities of Basiliximab.]
[L01BA03, raltitrexed, Tacrolimus may increase the immunosuppressive activities of Raltitrexed.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Tacrolimus.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Canrenone is combined with Tacrolimus.]
[R03BA02, budesonide, Tacrolimus may increase the immunosuppressive activities of Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Tacrolimus.]
[M01AB07, bumadizone, The risk or severity of renal failure can be increased when Bumadizone is combined with Tacrolimus.]
[L01EL02, acalabrutinib, The serum concentration of Tacrolimus can be increased when it is combined with Acalabrutinib.]
[J05AX18, letermovir, The serum concentration of Tacrolimus can be increased when it is combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Tacrolimus may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Tacrolimus.]
[N01BX04, capsaicin, The serum concentration of Tacrolimus can be increased when it is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Tacrolimus.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Tacrolimus can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Tacrolimus may increase the immunosuppressive activities of Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Tacrolimus.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-n1.]
[C07AG02, carvedilol, Carvedilol may increase the immunosuppressive activities of Tacrolimus.]
[B02BX09, fostamatinib, The serum concentration of Tacrolimus can be increased when it is combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Tacrolimus can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Tacrolimus.]
[L04AA37, baricitinib, Tacrolimus may increase the immunosuppressive activities of Baricitinib.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefpodoxime.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Tacrolimus.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftibuten.]
[J01GB14, plazomicin, Tacrolimus may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Tacrolimus.]
[L01XX62, ivosidenib, The metabolism of Tacrolimus can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Tacrolimus may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Tacrolimus can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Tacrolimus.]
[J05AX24, tecovirimat, The metabolism of Tacrolimus can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Tacrolimus can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Tacrolimus can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Tacrolimus.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Tacrolimus.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Tacrolimus.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Tacrolimus.]
[D08AE05, chloroxylenol, Tacrolimus may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of renal failure can be increased when Lornoxicam is combined with Tacrolimus.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Tacrolimus.]
[R03BB08, revefenacin, Tacrolimus may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Tacrolimus can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, Tacrolimus may increase the immunosuppressive activities of Emapalumab.]
[L01AD01, carmustine, Tacrolimus may increase the immunosuppressive activities of Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Tacrolimus.]
[L01EX13, gilteritinib, The metabolism of Tacrolimus can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amifampridine.]
[L04AA43, ravulizumab, Tacrolimus may increase the immunosuppressive activities of Ravulizumab.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Tacrolimus.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Tacrolimus.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Tacrolimus.]
[C10AB08, ciprofibrate, Tacrolimus may increase the nephrotoxic activities of Ciprofibrate.]
[P02BX04, triclabendazole, The serum concentration of Tacrolimus can be increased when it is combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Tacrolimus can be increased when combined with Esketamine.]
[L04AA42, siponimod, Tacrolimus may increase the immunosuppressive activities of Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, Tacrolimus may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Tacrolimus.]
[N05BA09, clobazam, The metabolism of Tacrolimus can be increased when combined with Clobazam.]
[D07AB21, clocortolone, Tacrolimus may increase the immunosuppressive activities of Clocortolone.]
[H02AB14, cloprednol, Tacrolimus may increase the immunosuppressive activities of Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ubidecarenone.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Candesartan.]
[L04AB01, etanercept, Tacrolimus may increase the immunosuppressive activities of Etanercept.]
[V03AE02, sevelamer, The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer.]
[H02AB17, cortivazol, Tacrolimus may increase the immunosuppressive activities of Cortivazol.]
[L04AC18, risankizumab, Tacrolimus may increase the immunosuppressive activities of Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Tacrolimus can be increased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Tacrolimus.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefazolin.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Tacrolimus.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Tacrolimus.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefonicid.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Tacrolimus.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tacrolimus.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Tacrolimus.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tacrolimus.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefuroxime.]
[L04AA44, upadacitinib, Tacrolimus may increase the immunosuppressive activities of Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Tacrolimus.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Tacrolimus can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Tacrolimus can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Tacrolimus.]
[N04CX01, istradefylline, The metabolism of Tacrolimus can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Tacrolimus.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Tacrolimus.]
[J01DB01, cephalexin, The metabolism of Tacrolimus can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Tacrolimus.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefapirin.]
[J01DB09, cephradine, The metabolism of Tacrolimus can be increased when combined with Cefradine.]
[H02AB13, deflazacort, Tacrolimus may increase the immunosuppressive activities of Deflazacort.]
[L01FD01, trastuzumab, Tacrolimus may increase the immunosuppressive activities of Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, Tacrolimus may increase the immunosuppressive activities of Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Tacrolimus.]
[L04AX09, diroximel fumarate, Tacrolimus may increase the immunosuppressive activities of Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Tacrolimus.]
[B06AX03, voxelotor, The serum concentration of Tacrolimus can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Tacrolimus can be increased when it is combined with Cenobamate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Givosiran.]
[M09AX08, golodirsen, Tacrolimus may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Tacrolimus.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tacrolimus.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tacrolimus.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Tacrolimus may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N05CM21, lemborexant, The metabolism of Tacrolimus can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tacrolimus can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, Tacrolimus may increase the immunosuppressive activities of Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Tacrolimus.]
[J05AB16, remdesivir, The serum concentration of Tacrolimus can be increased when it is combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Tacrolimus can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Tacrolimus can be increased when it is combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Tacrolimus can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Tacrolimus may increase the immunosuppressive activities of Ozanimod.]
[L01EE04, selumetinib, The metabolism of Tacrolimus can be decreased when combined with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Tacrolimus may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Tacrolimus may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[D07AC19, difluprednate, Tacrolimus may increase the immunosuppressive activities of Difluprednate.]
[M01AH02, rofecoxib, The risk or severity of renal failure can be increased when Rofecoxib is combined with Tacrolimus.]
[L01XF03, bexarotene, Tacrolimus may increase the immunosuppressive activities of Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Tacrolimus can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Dirithromycin.]
[L01AA02, chlorambucil, Tacrolimus may increase the immunosuppressive activities of Chlorambucil.]
[S03AA08, chloramphenicol, The serum concentration of Tacrolimus can be increased when it is combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Tacrolimus.]
[D07XB03, fluprednidene, Tacrolimus may increase the immunosuppressive activities of Fluprednidene.]
[M01AC04, droxicam, The risk or severity of renal failure can be increased when Droxicam is combined with Tacrolimus.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Tacrolimus.]
[V08CA05, mangafodipir, Tacrolimus may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.]
[M02AA27, dexketoprofen, The risk or severity of renal failure can be increased when Dexketoprofen is combined with Tacrolimus.]
[L04AA47, inebilizumab, Tacrolimus may increase the immunosuppressive activities of Inebilizumab.]
[R05CB11, stepronin, Tacrolimus may increase the immunosuppressive activities of Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Tacrolimus can be increased when it is combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Tacrolimus can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Tacrolimus.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus.]
[L04AC19, satralizumab, The serum concentration of Tacrolimus can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Tacrolimus can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Tacrolimus can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Tacrolimus.]
[R06AB04, chlorpheniramine, The metabolism of Tacrolimus can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Tacrolimus can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, Tacrolimus may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Tacrolimus.]
[N02BA07, ethenzamide, The risk or severity of renal failure can be increased when Ethenzamide is combined with Tacrolimus.]
[N02BA03, choline salicylate, Tacrolimus may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Vinpocetine may increase the immunosuppressive activities of Tacrolimus.]
[M01AB08, etodolac, The risk or severity of renal failure can be increased when Etodolac is combined with Tacrolimus.]
[M02AA06, etofenamate, The risk or severity of renal failure can be increased when Etofenamate is combined with Tacrolimus.]
[C10AB09, etofibrate, Tacrolimus may increase the nephrotoxic activities of Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Tacrolimus.]
[A16AX20, lonafarnib, The serum concentration of Tacrolimus can be increased when it is combined with Lonafarnib.]
[L01BB05, fludarabine, Tacrolimus may increase the immunosuppressive activities of Fludarabine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Tacrolimus.]
[M01AX25, chondroitin sulfates, Tacrolimus may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, Tacrolimus may increase the immunosuppressive activities of Voclosporin.]
[P03AX07, abametapir, The serum concentration of Tacrolimus can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Tacrolimus.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Tacrolimus.]
[N03AX10, felbamate, The metabolism of Tacrolimus can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of renal failure can be increased when Fenbufen is combined with Tacrolimus.]
[C01CA19, fenoldopam, Tacrolimus may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Tacrolimus can be decreased when combined with Finasteride.]
[J01DD15, cefdinir, Tacrolimus may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Flumequine.]
[R03BA03, flunisolide, Tacrolimus may increase the immunosuppressive activities of Flunisolide.]
[N02BG07, flupirtine, Tacrolimus may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Tacrolimus.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Tacrolimus.]
[L03AB10, peginterferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tacrolimus.]
[A02BA01, cimetidine, The serum concentration of Tacrolimus can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Tacrolimus may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the immunosuppressive activities of Tacrolimus.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Tacrolimus can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Tacrolimus can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The serum concentration of Tacrolimus can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Tacrolimus may increase the immunosuppressive activities of Cisplatin.]
[N06AB04, citalopram, The serum concentration of Tacrolimus can be increased when it is combined with Citalopram.]
[L04AA54, pegcetacoplan, Tacrolimus may increase the immunosuppressive activities of Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Tacrolimus.]
[L04AA48, belumosudil, Tacrolimus may increase the immunosuppressive activities of Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Tacrolimus can be increased when it is combined with Fexinidazole.]
[L04AA51, anifrolumab, Tacrolimus may increase the immunosuppressive activities of Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Tacrolimus can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Tacrolimus.]
[V09AB03, ioflupane I-123, Tacrolimus may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Tacrolimus.]
[V09AA01, technetium Tc 99m exametazime, Tacrolimus may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Tacrolimus may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L04AA59, avacopan, The metabolism of Tacrolimus can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus.]
[J01FF01, clindamycin, The serum concentration of Tacrolimus can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Tacrolimus can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Tacrolimus can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Tacrolimus can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, Tacrolimus may increase the immunosuppressive activities of Clobetasol.]
[J04BA01, clofazimine, The serum concentration of Tacrolimus can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Tacrolimus.]
[C10AB01, clofibrate, Tacrolimus may increase the nephrotoxic activities of Clofibrate.]
[B06AX04, mitapivat, The metabolism of Tacrolimus can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Tacrolimus may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Tacrolimus can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Tacrolimus.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Tacrolimus.]
[N03AE01, clonazepam, Tacrolimus may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Tacrolimus.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Tacrolimus.]
[C01EB24, mavacamten, The serum concentration of Tacrolimus can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Tacrolimus may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Tacrolimus.]
[A02BC08, vonoprazan, The metabolism of Tacrolimus can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, Tacrolimus may increase the immunosuppressive activities of Spesolimab.]
[L04AA56, deucravacitinib, Tacrolimus may increase the immunosuppressive activities of Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Tacrolimus can be decreased when combined with Ondansetron.]
[G01AF02, clotrimazole, The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Tacrolimus can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The serum concentration of Tacrolimus can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The serum concentration of Tacrolimus can be increased when it is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Tacrolimus.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Tacrolimus.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Tacrolimus.]
[J01GB12, arbekacin, Tacrolimus may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, Tacrolimus may increase the immunosuppressive activities of Halometasone.]
[H01AC08, somatrogon, The metabolism of Tacrolimus can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cocaine.]
[L04AC21, bimekizumab, Tacrolimus may increase the immunosuppressive activities of Bimekizumab.]
[M01AX13, proquazone, The risk or severity of renal failure can be increased when Proquazone is combined with Tacrolimus.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Tacrolimus.]
[J01XB01, colistin, Tacrolimus may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefpirome.]
[L04AA13, leflunomide, Tacrolimus may increase the immunosuppressive activities of Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Desflurane.]
[A04AA03, tropisetron, Tacrolimus may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The metabolism of Tacrolimus can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure can be increased when Imidazole salicylate is combined with Tacrolimus.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Tacrolimus.]
[L01BB07, nelarabine, Tacrolimus may increase the immunosuppressive activities of Nelarabine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Tacrolimus.]
[J01FA15, telithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, Tacrolimus may increase the immunosuppressive activities of Ciclesonide.]
[B01AC10, indobufen, The risk or severity of renal failure can be increased when Indobufen is combined with Tacrolimus.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Desloratadine.]
[J05AB14, valganciclovir, Tacrolimus may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Tacrolimus may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Tacrolimus may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Tacrolimus may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Tacrolimus may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Tacrolimus may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of renal failure can be increased when Valdecoxib is combined with Tacrolimus.]
[N02CC05, almotriptan, Tacrolimus may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of renal failure can be increased when Parecoxib is combined with Tacrolimus.]
[J02AC02, itraconazole, The serum concentration of Tacrolimus can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Tacrolimus.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Emedastine.]
[N05BA10, ketazolam, The serum concentration of Tacrolimus can be increased when it is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of renal failure can be increased when Kebuzone is combined with Tacrolimus.]
[L01EA01, imatinib, The serum concentration of Tacrolimus can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Tacrolimus can be increased when it is combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Tacrolimus can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, Lacidipine may increase the immunosuppressive activities of Tacrolimus.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Tacrolimus.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Tacrolimus.]
[S01BA03, cortisone, The metabolism of Tacrolimus can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of renal failure can be increased when Lonazolac is combined with Tacrolimus.]
[M02AA31, loxoprofen, The risk or severity of renal failure can be increased when Loxoprofen is combined with Tacrolimus.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tacrolimus.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Tacrolimus.]
[A06AD01, magnesium carbonate, Tacrolimus may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The serum concentration of Tacrolimus can be increased when it is combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Mebeverine.]
[S01BA08, medrysone, Tacrolimus may increase the immunosuppressive activities of Medrysone.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Mepindolol.]
[H02AB15, meprednisone, Tacrolimus may increase the immunosuppressive activities of Meprednisone.]
[R06AD07, mequitazine, The serum concentration of Tacrolimus can be increased when it is combined with Mequitazine.]
[J01DH02, meropenem, Tacrolimus may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Adenosine.]
[C04AX01, cyclandelate, Cyclandelate may increase the immunosuppressive activities of Tacrolimus.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Cyclizine.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tacrolimus.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Melperone.]
[L04AA15, alefacept, Tacrolimus may increase the immunosuppressive activities of Alefacept.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Tacrolimus.]
[J01FA03, midecamycin, The serum concentration of Tacrolimus can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Tacrolimus.]
[J05AF07, tenofovir disoproxil, Tacrolimus may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, Tacrolimus may increase the immunosuppressive activities of Cyclophosphamide.]
[S01XA18, cyclosporine, Tacrolimus may increase the nephrotoxic activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Tacrolimus can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Tacrolimus.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Tacrolimus.]
[C10AA07, rosuvastatin, The metabolism of Tacrolimus can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of renal failure can be increased when Mofebutazone is combined with Tacrolimus.]
[M01AX22, morniflumate, The risk or severity of renal failure can be increased when Morniflumate is combined with Tacrolimus.]
[C03XA02, conivaptan, The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan.]
[L01BC01, cytarabine, Tacrolimus may increase the immunosuppressive activities of Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Tacrolimus.]
[M01AH05, etoricoxib, The serum concentration of Tacrolimus can be increased when it is combined with Etoricoxib.]
[L01AX04, dacarbazine, Tacrolimus may increase the immunosuppressive activities of Dacarbazine.]
[L01DA01, dactinomycin, Tacrolimus may increase the immunosuppressive activities of Dactinomycin.]
[G03XA01, danazol, The serum concentration of Tacrolimus can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Tacrolimus can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of renal failure can be increased when Nabumetone is combined with Tacrolimus.]
[N07BB05, nalmefene, Tacrolimus may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Tacrolimus.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nebivolol.]
[S01GX04, nedocromil, Tacrolimus may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The serum concentration of Tacrolimus can be increased when it is combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nicorandil.]
[L02BB02, nilutamide, Tacrolimus may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Tacrolimus may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, Tacrolimus may increase the immunosuppressive activities of Pimecrolimus.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of renal failure can be increased when Olsalazine is combined with Tacrolimus.]
[N06AA01, desipramine, The serum concentration of Tacrolimus can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, Tacrolimus may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[S01BA11, desonide, Tacrolimus may increase the immunosuppressive activities of Desonide.]
[D07XC02, desoximetasone, Tacrolimus may increase the immunosuppressive activities of Desoximetasone.]
[V04CH02, indigo carmine, Tacrolimus may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, The serum concentration of Tacrolimus can be increased when it is combined with Ertapenem.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Aliskiren.]
[L01XA03, oxaliplatin, Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of renal failure can be increased when Oxaprozin is combined with Tacrolimus.]
[N03AF02, oxcarbazepine, The serum concentration of Tacrolimus can be increased when it is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Tacrolimus can be increased when it is combined with Dexamethasone.]
[G04BD04, oxybutynin, The serum concentration of Tacrolimus can be increased when it is combined with Oxybutynin.]
[L04AB04, adalimumab, Tacrolimus may increase the immunosuppressive activities of Adalimumab.]
[L01EB01, gefitinib, The metabolism of Tacrolimus can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Tacrolimus may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Tacrolimus can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The serum concentration of Tacrolimus can be increased when it is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Tacrolimus can be decreased when combined with Clopidogrel.]
[A03AX15, peppermint oil, The serum concentration of Tacrolimus can be increased when it is combined with Peppermint oil.]
[P03AC04, permethrin, Tacrolimus may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The serum concentration of Tacrolimus can be increased when it is combined with Diazepam.]
[R05DA08, pholcodine, Tacrolimus may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of renal failure can be increased when Diclofenac is combined with Tacrolimus.]
[J01CF01, dicloxacillin, The metabolism of Tacrolimus can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Foscarnet.]
[A03AA07, dicyclomine, Tacrolimus may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Tacrolimus may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, Pinaverium may increase the immunosuppressive activities of Tacrolimus.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus.]
[L01DC04, ixabepilone, Tacrolimus may increase the immunosuppressive activities of Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Tacrolimus can be increased when it is combined with Erlotinib.]
[L01DB08, pirarubicin, Tacrolimus may increase the immunosuppressive activities of Pirarubicin.]
[L02AA01, diethylstilbestrol, The serum concentration of Tacrolimus can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The serum concentration of Tacrolimus can be increased when it is combined with Isradipine.]
[D07XC04, diflucortolone, Tacrolimus may increase the immunosuppressive activities of Difluocortolone.]
[N02BA11, diflunisal, The risk or severity of renal failure can be increased when Diflunisal is combined with Tacrolimus.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Tacrolimus.]
[C01AA05, digoxin, Tacrolimus may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, The excretion of Ezetimibe can be decreased when combined with Tacrolimus.]
[L01XX24, pegaspargase, Tacrolimus may increase the immunosuppressive activities of Pegaspargase.]
[C04AE04, dihydroergocristine, The metabolism of Tacrolimus can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The serum concentration of Tacrolimus can be increased when it is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Tacrolimus may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Tacrolimus may increase the immunosuppressive activities of Lenalidomide.]
[J05AE08, atazanavir, The serum concentration of Tacrolimus can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Tacrolimus.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Tacrolimus.]
[V03AB04, pralidoxime, Tacrolimus may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D07AC18, prednicarbate, Tacrolimus may increase the immunosuppressive activities of Prednicarbate.]
[C08DB01, diltiazem, The serum concentration of Tacrolimus can be increased when it is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Tacrolimus may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The serum concentration of Tacrolimus can be increased when it is combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of renal failure can be increased when Propyphenazone is combined with Tacrolimus.]
[M01AB14, proglumetacin, The risk or severity of renal failure can be increased when Proglumetacin is combined with Tacrolimus.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Tacrolimus.]
[C05CA03, diosmin, The metabolism of Tacrolimus can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tacrolimus.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tacrolimus.]
[A03FA02, cisapride, The metabolism of Tacrolimus can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Tacrolimus.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus.]
[S01AX06, resorcinol, Tacrolimus may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tacrolimus.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Tacrolimus can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Tacrolimus can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tacrolimus can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Tacrolimus.]
[N05AX08, risperidone, The metabolism of Tacrolimus can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levocetirizine.]
[L04AA21, efalizumab, Tacrolimus may increase the immunosuppressive activities of Efalizumab.]
[N01BB09, ropivacaine, Tacrolimus may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Tacrolimus.]
[L01EX01, sunitinib, The serum concentration of Tacrolimus can be increased when it is combined with Sunitinib.]
[A04AD12, aprepitant, The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Tacrolimus.]
[L01XG01, bortezomib, Tacrolimus may increase the immunosuppressive activities of Bortezomib.]
[J05AE07, fosamprenavir, The metabolism of Tacrolimus can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Tacrolimus can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The risk or severity of renal failure can be increased when Ketorolac is combined with Tacrolimus.]
[C02KX02, ambrisentan, The metabolism of Tacrolimus can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Tacrolimus.]
[N02BA06, salsalate, The risk or severity of renal failure can be increased when Salsalate is combined with Tacrolimus.]
[R03AC12, salmeterol, The metabolism of Tacrolimus can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, Tacrolimus may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Tacrolimus may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Tacrolimus can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Tacrolimus may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Tacrolimus can be increased when it is combined with Doxorubicin.]
[J01AA02, doxycycline, Tacrolimus may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Tacrolimus.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Droperidol.]
[A08AA10, sibutramine, Tacrolimus may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Tacrolimus can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Tacrolimus.]
[A12CA02, sodium sulfate, Tacrolimus may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Spirapril.]
[R03DA01, dyphylline, Tacrolimus may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sultopride.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Tacrolimus.]
[V04CX07, edrophonium, Tacrolimus may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Tacrolimus.]
[H01AA01, corticotropin, Tacrolimus may increase the immunosuppressive activities of Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Temafloxacin.]
[L01AX03, temozolomide, Tacrolimus may increase the immunosuppressive activities of Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of renal failure can be increased when Tenoxicam is combined with Tacrolimus.]
[D01BA02, terbinafine, The metabolism of Tacrolimus can be increased when combined with Terbinafine.]
[G04BD05, terodiline, Terodiline may increase the immunosuppressive activities of Tacrolimus.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Tertatolol.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Tacrolimus.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Tacrolimus.]
[G01AF08, tioconazole, The serum concentration of Tacrolimus can be increased when it is combined with Tioconazole.]
[N05BA23, tofisopam, The serum concentration of Tacrolimus can be increased when it is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure can be increased when Tolfenamic acid is combined with Tacrolimus.]
[N06AG03, toloxatone, Tacrolimus may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Tacrolimus.]
[N03AX11, topiramate, The metabolism of Tacrolimus can be increased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Toremifene.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Tacrolimus.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Tacrolimus.]
[N05CC01, chloral hydrate, Tacrolimus may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Tacrolimus.]
[H02CA01, trilostane, Tacrolimus may increase the immunosuppressive activities of Trilostane.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Triptorelin.]
[L01AA07, trofosfamide, Tacrolimus may increase the immunosuppressive activities of Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Tacrolimus.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Tacrolimus.]
[L01CA04, vinorelbine, Tacrolimus may increase the immunosuppressive activities of Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Tacrolimus.]
[N06AX16, venlafaxine, Tacrolimus may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[S01GA03, xylometazoline, Xylometazoline may increase the immunosuppressive activities of Tacrolimus.]
[C08CA12, mepirodipine, The serum concentration of Tacrolimus can be increased when it is combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Tacrolimus can be increased when it is combined with Epinephrine.]
[L01DB03, epirubicin, Tacrolimus may increase the immunosuppressive activities of Epirubicin.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of renal failure can be increased when Zomepirac is combined with Tacrolimus.]
[N03AX15, zonisamide, Zonisamide may increase the immunosuppressive activities of Tacrolimus.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Tacrolimus.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Tacrolimus.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Tacrolimus.]
[L01XA02, carboplatin, Tacrolimus may increase the immunosuppressive activities of Carboplatin.]
[C02AC02, guanfacine, Tacrolimus may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Tacrolimus.]
[N02CA02, ergotamine, The serum concentration of Tacrolimus can be increased when it is combined with Ergotamine.]
[N03AG01, valproic acid, The serum concentration of Tacrolimus can be increased when it is combined with Valproic acid.]
[L03AX05, pidotimod, Tacrolimus may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Tacrolimus may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, The metabolism of Tacrolimus can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Tacrolimus can be decreased when combined with Estradiol.]
[L01XX11, estramustine, Tacrolimus may increase the immunosuppressive activities of Estramustine.]
[G03CA57, estrogens, conjugated (USP), The excretion of Conjugated estrogens can be decreased when combined with Tacrolimus.]
[J04AK02, ethambutol, The metabolism of Tacrolimus can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The serum concentration of Tacrolimus can be increased when it is combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Tacrolimus can be increased when it is combined with Fluvastatin.]
[V08CA03, gadodiamide, Tacrolimus may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[D07AC21, halobetasol, Tacrolimus may increase the immunosuppressive activities of Ulobetasol.]
[L02AA03, ethinyl estradiol, The metabolism of Tacrolimus can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ibutilide.]
[N03AD01, ethosuximide, Ethosuximide may increase the immunosuppressive activities of Tacrolimus.]
[M01AC06, meloxicam, The risk or severity of renal failure can be increased when Meloxicam is combined with Tacrolimus.]
[N01AX07, etomidate, Tacrolimus may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Tacrolimus can be increased when it is combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ajmaline.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, Tacrolimus may increase the immunosuppressive activities of Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The serum concentration of Tacrolimus can be increased when it is combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, Tacrolimus may increase the immunosuppressive activities of Fluocinolone acetonide.]
[M01AG01, mefenamic acid, The risk or severity of renal failure can be increased when Mefenamic acid is combined with Tacrolimus.]
[C01DA05, pentaerythritol tetranitrate, Tacrolimus may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The serum concentration of Tacrolimus can be increased when it is combined with Fluticasone furoate.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Tacrolimus can be increased when it is combined with Astemizole.]
[R06AX12, terfenadine, The serum concentration of Tacrolimus can be increased when it is combined with Terfenadine.]
[P01AX07, trimetrexate, Tacrolimus may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Tacrolimus may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The serum concentration of Tacrolimus can be increased when it is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrolimus.]
[L04AA02, muromonab-CD3, Tacrolimus may increase the immunosuppressive activities of Muromonab.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Tacrolimus.]
[M01CB01, gold sodium thiomalate, Tacrolimus may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Tacrolimus may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Tacrolimus may increase the immunosuppressive activities of Dexrazoxane.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Famotidine.]
[A16AA01, levocarnitine, Tacrolimus may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Tacrolimus can be decreased when combined with Albendazole.]
[C08CA02, felodipine, Felodipine may increase the immunosuppressive activities of Tacrolimus.]
[C08EA01, fendiline, Fendiline may increase the immunosuppressive activities of Tacrolimus.]
[M01AE04, fenoprofen, The risk or severity of renal failure can be increased when Fenoprofen is combined with Tacrolimus.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Tacrolimus.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Tacrolimus.]
[L01BB06, clofarabine, Tacrolimus may increase the immunosuppressive activities of Clofarabine.]
[L04AA40, cladribine, Tacrolimus may increase the immunosuppressive activities of Cladribine.]
[N07AX03, cevimeline, Tacrolimus may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Tacrolimus may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of renal failure can be increased when Floctafenine is combined with Tacrolimus.]
[J01CF05, floxacillin, The metabolism of Tacrolimus can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Tacrolimus can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Tacrolimus may increase the immunosuppressive activities of Flucytosine.]
[H02AA02, fludrocortisone, Tacrolimus may increase the immunosuppressive activities of Fludrocortisone.]
[V03AB25, flumazenil, Tacrolimus may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, Tacrolimus may increase the immunosuppressive activities of Flumethasone.]
[N07CA03, flunarizine, Flunarizine may increase the immunosuppressive activities of Tacrolimus.]
[D07AC08, fluocinonide, Tacrolimus may increase the immunosuppressive activities of Fluocinonide.]
[H02AB03, fluocortolone, Tacrolimus may increase the immunosuppressive activities of Fluocortolone.]
[V03AZ01, ethanol, Ethanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01BC09, floxuridine, Tacrolimus may increase the immunosuppressive activities of Floxuridine.]
[S01CB05, fluorometholone, Tacrolimus may increase the immunosuppressive activities of Fluorometholone.]
[L01BC02, fluorouracil, Tacrolimus may increase the immunosuppressive activities of Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Tacrolimus.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tacrolimus.]
[D07AC07, flurandrenolide, Tacrolimus may increase the immunosuppressive activities of Flurandrenolide.]
[N05CD01, flurazepam, Tacrolimus may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of renal failure can be increased when Flurbiprofen is combined with Tacrolimus.]
[N05AG01, fluspirilene, Fluspirilene may increase the immunosuppressive activities of Tacrolimus.]
[L02BB01, flutamide, The metabolism of Tacrolimus can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Tacrolimus may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Tacrolimus may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Tacrolimus.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Tacrolimus.]
[J05AE10, darunavir, The serum concentration of Tacrolimus can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Furosemide is combined with Tacrolimus.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Tacrolimus.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tacrolimus.]
[C08DA02, gallopamil, Gallopamil may increase the immunosuppressive activities of Tacrolimus.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ganciclovir.]
[N03AA04, barbexaclone, The metabolism of Tacrolimus can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, Tacrolimus may increase the nephrotoxic activities of Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Degarelix.]
[L01EA02, dasatinib, The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Tacrolimus can be increased when it is combined with Cabergoline.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Tacrolimus.]
[J05AG04, etravirine, The metabolism of Tacrolimus can be increased when combined with Etravirine.]
[N03AD03, methsuximide, Methsuximide may increase the immunosuppressive activities of Tacrolimus.]
[N01AH02, alfentanil, The metabolism of Tacrolimus can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Tacrolimus can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The serum concentration of Tacrolimus can be increased when it is combined with Glyburide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tacrolimus.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Tacrolimus.]
[N05CM18, dexmedetomidine, Tacrolimus may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Tacrolimus.]
[C02CA04, doxazosin, The metabolism of Tacrolimus can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Tacrolimus can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tacrolimus.]
[M01CB04, aurothioglucose, Tacrolimus may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Tacrolimus may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Tacrolimus.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tacrolimus.]
[D01BA01, griseofulvin, The metabolism of Tacrolimus can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Tacrolimus may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Tacrolimus can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, Tacrolimus may increase the immunosuppressive activities of Halcinonide.]
[N05AD01, haloperidol, The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Histrelin.]
[N05AH04, quetiapine, The metabolism of Tacrolimus can be decreased when combined with Quetiapine.]
[N06BX13, idebenone, Tacrolimus may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Tacrolimus.]
[L01CE02, irinotecan, Tacrolimus may increase the immunosuppressive activities of Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Tacrolimus.]
[C09CA01, losartan, The serum concentration of Tacrolimus can be increased when it is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Tacrolimus can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of renal failure can be increased when Mesalazine is combined with Tacrolimus.]
[C01CE02, milrinone, Tacrolimus may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, Tacrolimus may increase the immunosuppressive activities of Altretamine.]
[J05AG01, nevirapine, The metabolism of Tacrolimus can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The serum concentration of Tacrolimus can be increased when it is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure can be increased when Nimesulide is combined with Tacrolimus.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Tacrolimus.]
[C02DB02, hydralazine, The serum concentration of Tacrolimus can be increased when it is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Tacrolimus.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Tacrolimus.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Tacrolimus.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Tacrolimus.]
[V03AB33, hydroxocobalamin, Tacrolimus may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Tacrolimus may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, Tacrolimus may increase the immunosuppressive activities of Hydroxychloroquine.]
[B05AA07, hetastarch, Tacrolimus may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, Tacrolimus may increase the immunosuppressive activities of Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Tacrolimus can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, Tacrolimus may increase the immunosuppressive activities of Rimexolone.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of renal failure can be increased when Ibuprofen is combined with Tacrolimus.]
[B05XA08, sodium acetate, Tacrolimus may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Tacrolimus.]
[L01DB06, idarubicin, Tacrolimus may increase the immunosuppressive activities of Idarubicin.]
[L01AA06, ifosfamide, The serum concentration of Tacrolimus can be increased when it is combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Tacrolimus.]
[L01CD01, paclitaxel, Tacrolimus may increase the immunosuppressive activities of Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Terlipressin.]
[R01AD07, tixocortol, Tacrolimus may increase the immunosuppressive activities of Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Tacrolimus.]
[L01CE01, topotecan, The serum concentration of Tacrolimus can be increased when it is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Tacrolimus.]
[S01BC01, indomethacin, Tacrolimus may increase the immunosuppressive activities of Indomethacin.]
[A11HA07, inositol, Tacrolimus may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2b.]
[N06AX17, milnacipran, The serum concentration of Tacrolimus can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, Tacrolimus may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, Tacrolimus may increase the immunosuppressive activities of Eculizumab.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Tacrolimus.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Tacrolimus.]
[N05CH02, ramelteon, Tacrolimus may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Tacrolimus.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tacrolimus.]
[C10AA06, cerivastatin, The serum concentration of Tacrolimus can be increased when it is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, Tacrolimus may increase the immunosuppressive activities of Interferon alfacon-1.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Tacrolimus.]
[D06BB10, imiquimod, Tacrolimus may increase the immunosuppressive activities of Imiquimod.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Tacrolimus.]
[J04AC01, isoniazid, The serum concentration of Tacrolimus can be increased when it is combined with Isoniazid.]
[J05AX05, inosine pranobex, Tacrolimus may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Tacrolimus.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Tacrolimus.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Tacrolimus.]
[J01FA07, josamycin, The serum concentration of Tacrolimus can be increased when it is combined with Josamycin.]
[S01AA24, kanamycin, Tacrolimus may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Tacrolimus.]
[L04AC07, tocilizumab, Tacrolimus may increase the immunosuppressive activities of Tocilizumab.]
[N01AX03, ketamine, Tacrolimus may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Tacrolimus.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Tacrolimus.]
[J02AB02, ketoconazole, The serum concentration of Tacrolimus can be increased when it is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Tacrolimus.]
[M02AA10, ketoprofen, The risk or severity of renal failure can be increased when Ketoprofen is combined with Tacrolimus.]
[V03AC03, deferasirox, The metabolism of Tacrolimus can be increased when combined with Deferasirox.]
[L04AA24, abatacept, Tacrolimus may increase the immunosuppressive activities of Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Nalidixic acid.]
[C07AG01, labetalol, The risk or severity of hyperkalemia can be increased when Labetalol is combined with Tacrolimus.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amantadine.]
[A06AX03, lubiprostone, Tacrolimus may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Tacrolimus can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, Tacrolimus may increase the immunosuppressive activities of Mitomycin.]
[G03AD01, levonorgestrel, The metabolism of Tacrolimus can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Tacrolimus can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, Lidoflazine may increase the immunosuppressive activities of Tacrolimus.]
[S01AA21, amikacin, Tacrolimus may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Tacrolimus can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Tacrolimus.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Tacrolimus.]
[L01AD02, lomustine, Tacrolimus may increase the immunosuppressive activities of Lomustine.]
[A07DA03, loperamide, Loperamide may increase the immunosuppressive activities of Tacrolimus.]
[N05BA06, lorazepam, Tacrolimus may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Tacrolimus.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Tacrolimus may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Tacrolimus may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the immunosuppressive activities of Tacrolimus.]
[L01BA05, pralatrexate, Tacrolimus may increase the immunosuppressive activities of Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Tacrolimus can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tacrolimus.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Maprotiline.]
[C02BB01, mecamylamine, Tacrolimus may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[L01AA05, mechlorethamine, Tacrolimus may increase the immunosuppressive activities of Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure can be increased when Meclofenamic acid is combined with Tacrolimus.]
[C01AA08, medigoxin, Tacrolimus may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The serum concentration of Tacrolimus can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Dalteparin.]
[L01AA03, melphalan, Tacrolimus may increase the immunosuppressive activities of Melphalan.]
[N06DX01, memantine, Tacrolimus may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Tacrolimus can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Tacrolimus can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Tacrolimus may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Tacrolimus may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Tacrolimus can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Tacrolimus may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Tacrolimus can be decreased when combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dolasetron.]
[H01CB03, lanreotide, The serum concentration of Tacrolimus can be increased when it is combined with Lanreotide.]
[N07BC02, methadone, The serum concentration of Tacrolimus can be increased when it is combined with Methadone.]
[N06BA03, methamphetamine, Tacrolimus may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Tacrolimus.]
[H03BB02, methimazole, The serum concentration of Tacrolimus can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, Tacrolimus may increase the immunosuppressive activities of Pemetrexed.]
[A11HA02, pyridoxine, Tacrolimus may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[N02BG08, ziconotide, Ziconotide may increase the immunosuppressive activities of Tacrolimus.]
[L04AX03, methotrexate, Tacrolimus may increase the immunosuppressive activities of Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Tacrolimus may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tacrolimus.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Methyldopa.]
[V04CG05, methylene blue, The serum concentration of Tacrolimus can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The serum concentration of Tacrolimus can be increased when it is combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Tacrolimus.]
[H02AB04, methylprednisolone, Tacrolimus may increase the immunosuppressive activities of Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Tacrolimus can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Tacrolimus may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Tacrolimus can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Metoclopramide.]
[C03BA08, metolazone, Tacrolimus may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, The risk or severity of hyperkalemia can be increased when Metoprolol is combined with Tacrolimus.]
[P01AB01, metronidazole, The serum concentration of Tacrolimus can be increased when it is combined with Metronidazole.]
[V04CD01, metyrapone, The serum concentration of Tacrolimus can be increased when it is combined with Metyrapone.]
[S02AA13, miconazole, The serum concentration of Tacrolimus can be increased when it is combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of renal failure can be increased when Aminophenazone is combined with Tacrolimus.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Tacrolimus.]
[G03XB01, mifepristone, The serum concentration of Tacrolimus can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Tinzaparin.]
[J05AH01, zanamivir, Tacrolimus may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Tacrolimus.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Minocycline.]
[J01FA11, miocamycin, The serum concentration of Tacrolimus can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Tacrolimus can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Tacrolimus may increase the immunosuppressive activities of Mitoxantrone.]
[L03AC01, aldesleukin, The serum concentration of Tacrolimus can be increased when it is combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Tacrolimus can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Tacrolimus can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Tacrolimus.]
[A04AA05, palonosetron, Tacrolimus may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Tacrolimus may increase the immunosuppressive activities of Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Ammonium chloride.]
[L04AA52, ofatumumab, Tacrolimus may increase the immunosuppressive activities of Ofatumumab.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.]
[L04AA06, mycophenolic acid, Tacrolimus may increase the immunosuppressive activities of Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Tacrolimus can be increased when combined with Amobarbital.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Tacrolimus.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Tacrolimus.]
[G03XC01, raloxifene, The serum concentration of Tacrolimus can be increased when it is combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Tacrolimus.]
[N03AB05, fosphenytoin, The serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, Tacrolimus may increase the immunosuppressive activities of Interferon beta-1b.]
[C07AA12, nadolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nadolol.]
[J01CA04, amoxicillin, Tacrolimus may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The metabolism of Tacrolimus can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The serum concentration of Tacrolimus can be increased when it is combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Tacrolimus.]
[L04AC03, anakinra, Tacrolimus may increase the immunosuppressive activities of Anakinra.]
[N06BA01, amphetamine, Tacrolimus may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of renal failure can be increased when Naproxen is combined with Tacrolimus.]
[A10BG01, troglitazone, The metabolism of Tacrolimus can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, Tacrolimus may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Tacrolimus may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, The serum concentration of Tacrolimus can be increased when it is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Neomycin.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Tacrolimus.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Tacrolimus.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tacrolimus.]
[S01AA19, ampicillin, Tacrolimus may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Tacrolimus may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Tacrolimus may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The serum concentration of Tacrolimus can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Tacrolimus.]
[C01CE01, inamrinone, Tacrolimus may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, Tacrolimus may increase the immunosuppressive activities of Amsacrine.]
[C10AD02, niacin, The metabolism of Tacrolimus can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.]
[C08CA05, nifedipine, Nifedipine may increase the immunosuppressive activities of Tacrolimus.]
[M02AA17, niflumic acid, The risk or severity of renal failure can be increased when Niflumic acid is combined with Tacrolimus.]
[C08CA06, nimodipine, Nimodipine may increase the immunosuppressive activities of Tacrolimus.]
[C08CA07, nisoldipine, Nisoldipine may increase the immunosuppressive activities of Tacrolimus.]
[C08CA08, nitrendipine, Nitrendipine may increase the immunosuppressive activities of Tacrolimus.]
[R07AX01, nitric oxide, The serum concentration of Tacrolimus can be increased when it is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Tacrolimus.]
[N05CF03, zaleplon, The metabolism of Tacrolimus can be decreased when combined with Zaleplon.]
[N04BC05, pramipexole, Tacrolimus may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Tacrolimus may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[G03DC02, norethindrone, The metabolism of Tacrolimus can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The serum concentration of Tacrolimus can be increased when it is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Tacrolimus can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Tacrolimus.]
[R05DA07, noscapine, The serum concentration of Tacrolimus can be increased when it is combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Tacrolimus.]
[G02CA02, nylidrin, Nylidrin may increase the immunosuppressive activities of Tacrolimus.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Tacrolimus can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, Tacrolimus may increase the immunosuppressive activities of Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.]
[N02AA02, opium, Tacrolimus may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Tacrolimus.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Tacrolimus.]
[G04CA02, tamsulosin, Tacrolimus may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Tacrolimus.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Zoledronic acid.]
[J01CF04, oxacillin, Tacrolimus may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Tacrolimus may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Tacrolimus can be decreased when combined with Oxycodone.]
[A14AA05, oxymetholone, The serum concentration of Tacrolimus can be increased when it is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure can be increased when Oxyphenbutazone is combined with Tacrolimus.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Danaparoid.]
[J04AB30, capreomycin, Tacrolimus may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Tacrolimus can be increased when it is combined with Paramethasone.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Paromomycin.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Tacrolimus.]
[G04BD11, fesoterodine, Tacrolimus may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Penbutolol.]
[N05AG03, penfluridol, Penfluridol may increase the immunosuppressive activities of Tacrolimus.]
[M01CC01, penicillamine, Tacrolimus may increase the immunosuppressive activities of Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Tacrolimus.]
[J01CE09, penicillin G procaine, Tacrolimus may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.]
[N05CA01, pentobarbital, The metabolism of Tacrolimus can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Tacrolimus may increase the immunosuppressive activities of Pentostatin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Tacrolimus.]
[C08EX02, perhexiline, Perhexiline may increase the immunosuppressive activities of Tacrolimus.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tacrolimus.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Phenazopyridine.]
[N06AF03, phenelzine, The serum concentration of Tacrolimus can be increased when it is combined with Phenelzine.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Tacrolimus.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Tacrolimus.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Tacrolimus can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Tacrolimus.]
[V03AB36, phentolamine, Tacrolimus may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of renal failure can be increased when Phenylbutazone is combined with Tacrolimus.]
[A02BC06, dexlansoprazole, The metabolism of Tacrolimus can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, Tacrolimus may increase the immunosuppressive activities of Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levofloxacin.]
[L02BB03, bicalutamide, The serum concentration of Tacrolimus can be increased when it is combined with Bicalutamide.]
[B02BA01, vitamin K1, Tacrolimus may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tacrolimus.]
[C08CX01, mibefradil, The serum concentration of Tacrolimus can be increased when it is combined with Mibefradil.]
[S01EB01, pilocarpine, The serum concentration of Tacrolimus can be increased when it is combined with Pilocarpine.]
[N05AG02, pimozide, The serum concentration of Tacrolimus can be increased when it is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Tacrolimus.]
[J01CA12, piperacillin, Tacrolimus may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Tacrolimus can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Tacrolimus may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of renal failure can be increased when Piroxicam is combined with Tacrolimus.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefditoren.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Grepafloxacin.]
[J05AG02, delavirdine, The serum concentration of Tacrolimus can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The serum concentration of Tacrolimus can be increased when it is combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Tacrolimus.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Tacrolimus.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tacrolimus.]
[L04AC08, canakinumab, Tacrolimus may increase the immunosuppressive activities of Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Tacrolimus is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Tacrolimus.]
[J05AE03, ritonavir, The serum concentration of Tacrolimus can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Tacrolimus can be decreased when combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Tacrolimus.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Tacrolimus.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Tacrolimus.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Pitavastatin.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Tacrolimus can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, Tacrolimus may increase the immunosuppressive activities of Prednisolone.]
[H02AB07, prednisone, Tacrolimus may increase the immunosuppressive activities of Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Antazoline.]
[C01DX02, prenylamine, Prenylamine may increase the immunosuppressive activities of Tacrolimus.]
[P01BA03, primaquine, The serum concentration of Tacrolimus can be increased when it is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Tacrolimus can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Tacrolimus can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Probucol.]
[C01BA02, procainamide, Tacrolimus may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XB01, procarbazine, Tacrolimus may increase the immunosuppressive activities of Procarbazine.]
[C10AB05, fenofibrate, Tacrolimus may increase the nephrotoxic activities of Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Tacrolimus can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Propafenone.]
[A03AB05, propantheline, Tacrolimus may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Tacrolimus.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Tacrolimus.]
[N01AX10, propofol, The serum concentration of Tacrolimus can be increased when it is combined with Propofol.]
[N02AC04, propoxyphene, The serum concentration of Tacrolimus can be increased when it is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Tacrolimus can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, Tacrolimus may increase the immunosuppressive activities of Propylthiouracil.]
[N02CC04, rizatriptan, Tacrolimus may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tacrolimus.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Tacrolimus.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Tacrolimus.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Tacrolimus.]
[N07XX07, dalfampridine, Tacrolimus may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Tacrolimus may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Tacrolimus may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Tacrolimus.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Tacrolimus.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Tacrolimus can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Tacrolimus can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Tacrolimus can be increased when it is combined with Quinine.]
[D07AC10, diflorasone, Tacrolimus may increase the immunosuppressive activities of Diflorasone.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Tacrolimus.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Rescinnamine.]
[C02AA02, reserpine, The metabolism of Tacrolimus can be increased when combined with Reserpine.]
[J05AP01, ribavirin, Tacrolimus may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Tacrolimus can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The serum concentration of Tacrolimus can be increased when it is combined with Roxithromycin.]
[C05CA01, rutin, The serum concentration of Tacrolimus can be increased when it is combined with Rutin.]
[N02BA05, salicylamide, The risk or severity of renal failure can be increased when Salicylamide is combined with Tacrolimus.]
[A07EC01, sulfasalazine, Tacrolimus may increase the immunosuppressive activities of Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of renal failure can be increased when Salicylic acid is combined with Tacrolimus.]
[N05CA06, secobarbital, The metabolism of Tacrolimus can be increased when combined with Secobarbital.]
[L01FA03, obinutuzumab, Tacrolimus may increase the immunosuppressive activities of Obinutuzumab.]
[J01GB08, sisomicin, Tacrolimus may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Tacrolimus may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.]
[H01CB01, somatostatin, The serum concentration of Tacrolimus can be increased when it is combined with Somatostatin.]
[V04CC01, sorbitol, Tacrolimus may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sotalol.]
[L01CD04, cabazitaxel, Tacrolimus may increase the immunosuppressive activities of Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid.]
[D07AC16, hydrocortisone aceponate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone aceponate.]
[D07AB11, hydrocortisone probutate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone probutate.]
[D07AB02, hydrocortisone butyrate, Tacrolimus may increase the immunosuppressive activities of Hydrocortisone butyrate.]
[C01DA14, isosorbide mononitrate, Tacrolimus may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Tacrolimus can be increased when it is combined with Levoketoconazole.]
[D10AX03, azelaic acid, Tacrolimus may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure can be increased when Tiaprofenic acid is combined with Tacrolimus.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Etacrynic acid.]
